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ABSTRACT
BAYESIAN ADAPTIVE DESIGNS FOR EARLY PHASE CLINICAL TRIALS
Publication No.
Chunyan Cai, B.S.
Supervisory Professor: Ying Yuan, Ph.D.
My dissertation focuses mainly on Bayesian adaptive designs for phase I and phase II
clinical trials. It includes three specic topics: (1) proposing a novel two-dimensional
dose-nding algorithm for biological agents, (2) developing Bayesian adaptive screen-
ing designs to provide more ecient and ethical clinical trials, and (3) incorporating
missing late-onset responses to make an early stopping decision.
Treating patients with novel biological agents is becoming a leading trend in oncology.
Unlike cytotoxic agents, for which toxicity and ecacy monotonically increase with
dose, biological agents may exhibit non-monotonic patterns in their dose-response
relationships. Using a trial with two biological agents as an example, we propose a
phase I/II trial design to identify the biologically optimal dose combination (BODC),
which is dened as the dose combination of the two agents with the highest ecacy
and tolerable toxicity. A change-point model is used to reect the fact that the
dose-toxicity surface of the combinational agents may plateau at higher dose levels,
and a exible logistic model is proposed to accommodate the possible non-monotonic
pattern for the dose-ecacy relationship. During the trial, we continuously update
the posterior estimates of toxicity and ecacy and assign patients to the most appro-
vi
priate dose combination. We propose a novel dose-nding algorithm to encourage
sucient exploration of untried dose combinations in the two-dimensional space.
Extensive simulation studies show that the proposed design has desirable operating
characteristics in identifying the BODC under various patterns of dose-toxicity and
dose-ecacy relationships.
Trials of combination therapies for the treatment of cancer are playing an increas-
ingly important role in the battle against this disease. To more eciently handle
the large number of combination therapies that must be tested, we propose a novel
Bayesian phase II adaptive screening design to simultaneously select among possible
treatment combinations involving multiple agents. Our design is based on formulat-
ing the selection procedure as a Bayesian hypothesis testing problem in which the
superiority of each treatment combination is equated to a single hypothesis. Dur-
ing the trial conduct, we use the current values of the posterior probabilities of all
hypotheses to adaptively allocate patients to treatment combinations. Simulation
studies show that the proposed design substantially outperforms the conventional
multi-arm balanced factorial trial design. The proposed design yields a signicantly
higher probability for selecting the best treatment while at the same time allocating
substantially more patients to ecacious treatments. The proposed design is most
appropriate for the trials combining multiple agents and screening out the ecacious
combination to be further investigated. The proposed Bayesian adaptive phase II
screening design substantially outperformed the conventional complete factorial de-
sign. Our design allocates more patients to better treatments while at the same time
providing higher power to identify the best treatment at the end of the trial.
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Phase II trial studies usually are single-arm trials which are conducted to test the
ecacy of experimental agents and decide whether agents are promising to be sent to
phase III trials. Interim monitoring is employed to stop the trial early for futility to
avoid assigning unacceptable number of patients to inferior treatments. We propose
a Bayesian single-arm phase II design with continuous monitoring for estimating the
response rate of the experimental drug. To address the issue of late-onset responses,
we use a piece-wise exponential model to estimate the hazard function of time to
response data and handle the missing responses using the multiple imputation ap-
proach. We evaluate the operating characteristics of the proposed method through
extensive simulation studies. We show that the proposed method reduces the total
length of the trial duration and yields desirable operating characteristics for dierent
physician-specied lower bounds of response rate with dierent true response rates.
viii
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CHAPTER 1
Introduction
1.1 Dose-nding Design for Oncology Clinical Trials of Combinational
Biological Agents
The paradigm of oncology drug development is expanding from traditional
cytotoxic agents to biological agents [5, 17, 32]. Examples of biological agents include
biospecimens targeting a specic tumor pathway, gene products aiming for DNA
repair, and immunotherapies stimulating the immune system to attack a tumor.
These novel agents dier from traditional cytotoxic agents in a variety of ways.
For cytotoxic agents, toxicity and ecacy are typically assumed to monotonically
increase with dose level. However, for biological agents, toxicity may increase at low
dose levels and then approximately plateau at higher dose levels. For instance, when
the toxicity of a biological agent is related to the inhibition of a biological pathway,
the toxicity of the agent increases initially with dose since a high dose results in a
high degree of inhibition; once the inhibition is saturated, the toxicity may be (or
approximately) constant within a certain range of dose. In addition, the dose-ecacy
curves for the biological agents may follow a non-monotonic pattern, and ecacy may
even decrease at higher dose levels [17]. Therefore, traditional dose-nding designs
with a focus on nding the maximum tolerated dose (MTD) [3, 35, 46, 59] are not
suitable for trials of biological agents. Novel designs that consider both the toxicity
1
and ecacy of these agents are imperative.
Dose-nding designs that jointly model toxicity and ecacy are categorized as
phase I/II designs. Numerous phase I/II designs have been proposed for traditional
cytotoxic agents. Gooley et al. (1994) [16] proposed a phase I/II clinical trial in bone
marrow transplantation to nd a dose that balances the risks of two immunologic
complications. Thall and Russell (1998) [49] proposed a phase I/II design to nd
a dose satisfying both safety and ecacy requirements based on a trinary outcome.
O'Quigley, Hughes, and Fenton (2001) [33] presented a class of designs aiming to
identify the dose yielding the highest treatment success rate for HIV studies. Thall
and Cook (2004) [47] proposed a Bayesian phase I/II trial design based on trade-os
between toxicity and ecacy probabilities. Yin, Li, and Ji (2006) [58] developed
a phase I/II Bayesian dose-nding design using toxicity and ecacy odds ratios.
O'Quigley and Zohar (2006) [36] provided a comprehensive review of phase I/II
designs. All of these phase I/II designs focus on single-agent trials and are not
directly applicable to trials evaluating combinational agents.
For drug combination trials, a number of designs have been proposed to nd
the MTD of cytotoxic agents. Simon and Korn (1990) [42] described a mathematical
model for the toxicity probability as a function of the weighted sum of the two doses to
select cytotoxic drugs and dosages for a combination regimen. Afterwards, Korn and
Simon (1993) [26] constructed a tolerable-dose diagram based on this simple mathe-
matical model to guide the phase I trial design. Kramar, Lebecq and Candalh (1999)
[27] proposed monotonically ordering of a selected subset of drug combinations which
reduced the dose nding to a one-dimensional space. Thall et al. (2003) [48] devel-
oped a six-parameter logistic regression model of the toxicity probability to identify
an entire \contour" of combinations. Conaway et al. (2004) [10] examined the simple
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and partial orders for drug combinations based on the pool adjacent violators algo-
rithm. Wang and Ivanova (2005) [53] proposed a two-stage Bayesian adaptive design
to identify MTD combinations based on a logistic-type regression for toxicity proba-
bilities. Yuan and Yin (2008) [60] proposed an adaptive two-dimensional dose-nding
design that can accommodate any type of single-agent dose-nding method. They
converted the two-dimensional dose-nding trial to a series of one-dimensional dose-
nding subtrials and conducted the subtrials sequentially. Braun and Wang (2009)
[6] proposed a hierarchical model for the dose-limiting toxicities (DLT) probability
to identify MTD for novel combinations of cancer therapeutic agents which consider
the subject heterogeneity for DLT. Recently, Wages, Conaway and O'Quigley (2011)
[52] extended the continual reassessment method (CRM) to two-dimensional dose
nding by converting a partially ordered two-dimensional dose space into a series of
fully ordered dose sequences. All of these designs focus on phase I dose nding for
cytotoxic agents and do not consider ecacy.
Published research on designs for phase I/II combination trials, in particular
for biological agents, has been very limited. Yuan and Yin (2011) [61] developed a
phase I/II design for drug combination trials, but that design focused on cytotoxic
agents. Mandrekar, Cui and Sargent (2007) [31] proposed a novel phase I/II design
for trials evaluating combinational biological agents based on a continuation ratio
model for trinary outcomes (namely, \no response," \success" and \toxicity"). Our
approach diers in several aspects: we model toxicity and ecacy as bivariate bi-
nary outcomes, use a change-point model to render the exibility to consider that
toxicity may plateau at high dose levels, and introduce a novel dose-nding algo-
rithm to stochastically search the two-dimensional dose space, thereby encouraging
the exploration of untried dose combinations.
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Our research is motivated by a drug-combination trial at The University
of Texas MD Anderson Cancer Center for patients diagnosed with relapsed lym-
phoma. The trial combined two novel biological agents, A and B (their names are
masked to maintain condentiality), that target two dierent components in the
PI3K/AKT/mTOR signaling pathway. This pathway has been associated with sev-
eral genetic aberrations related to the promotion of cancer [18]. Agent A is a PI3K
kinase inhibitor and agent B is a downstream inhibitor of mTOR kinase within that
pathway. Research has suggested that some types of lymphomas are promoted and
maintained by the activation of the PI3K/AKT/mTOR pathway, making the path-
way an important target for drug development [44]. Both agents A and B have
individually demonstrated a partial inhibition of the pathway and some therapeutic
activity. By combining these two agents, the investigators expect to obtain a more
complete inhibition of the PI3k/AKT/mTOR pathway, and thereby to achieve better
treatment responses. The trial investigates the combinations of 4 dose levels of agent
A with 4 dose levels of agent B, which results in 16 dose combinations. The goal is to
nd the biologically optimal dose combination (BODC), dened as the dose combina-
tion with the highest ecacy and tolerable toxicity (e.g., with a toxicity probability
< 0:4). The physicians expect the toxicity of the combinations to increase at low
doses and become (approximately) at at high doses, and they consider the possi-
bility that the dose-ecacy curve of the combinations may be non-monotonic (i.e.,
the dose with the highest ecacy is not necessarily the highest dose).
We introduce a phase I/II design to identify the BODC for oncology trials
of combinational biological agents. The proposed design explicitly accounts for the
unique properties of biological agents. We propose a change-point model to reect
the property that the dose-toxicity surface of the combinational agents may plateau
4
at higher dose levels, and use a general logistic model with quadratic terms to ac-
commodate the possible non-monotonic pattern of the dose-ecacy relationship. Our
design is conducted in two stages: in stage I, we escalate doses along the diagonal
of the dose combination matrix as a fast exploration of the dosing space; in stage
II, based on the observed toxicity and ecacy data from stages I and II, we con-
tinuously update the posterior estimates of toxicity and ecacy and assign patients
to the most appropriate dose combination. We propose a novel dose-nding algo-
rithm to encourage sucient exploration of the two-dimensional dose space, which
facilitates the identication of the BODC. Extensive simulation studies show that
the proposed design has desirable operating characteristics in identifying the BODC
under various patterns of dose-toxicity and dose-ecacy relationships.
1.2 Screening Design for Combination Trials Combining Multiple Agents
The use of combination therapies [28, 38, 62] for cancer treatment can lead
to treatment synergies that result in improved patient outcomes. The number of
treatment combinations that must be tested is often quite large, however, which
means that it is often not practical to conduct separate phase II trials on every
possible combination of treatments. We describe a Bayesian adaptive trial design
that facilitates the pooling of information obtained across treatment combinations
by testing ecacy of all treatment combinations in a single trial. Important benets
of our trial designs include a reduction in the number of patients that must be
recruited in order to evaluate each treatment combination, the assignment of a higher
proportion of patients to ecacious treatments, faster patient accrual and more rapid
completion of trials.
To motivate our design methodology, we consider a recent drug-combination
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clinical trial conducted at MD Anderson Cancer Center to test the eectiveness of
16 combinations of 4 agents, A1; A2; A3 and A4, in reducing the symptom burden
experienced by patients with late stage non-small cell lung cancer (NSCLC) who
have received chemo-radiation therapies. The actual names of the drugs assessed in
the trial are not specied here for reasons of condentiality. The primary outcome
variable for this trial was the area under the curve (AUC) for ve symptoms (pain,
fatigue, drowsiness, sleep disturbance and lack of appetite) measured daily using an
interactive voice recording system (IVR) for 10 days following the onset of radiation
therapy. Each symptom was measured using the MD Anderson Symptom Inventory
(MDASI), which solicits ordinal ratings of symptoms on an 11-point scale ranging
from 0 (\none at all") to 10 (\worst that can be imagined") [20]. In contrast to
typical cancer-treating agents, which are generally cytotoxic, the combinations of
four agents tested in this trial were known to have minimal risks of toxicity, and
thus we focused herein on ecacy only. The goal of the trial is to identify the most
ecacious combination to be further investigated in large trials.
A variety of screening designs have been proposed for use in trials of this gen-
eral type. Among these, Thall, Simon and Ellenberg (1988) [50] proposed a two-stage
phase II-III trial design to select the most promising treatment from k treatments in
the rst stage, and to compare the selected rst stage treatment with the standard of
care in the second stage. Schaid, Wieand and Therneau (1990) [41] presented a simi-
lar two-stage design that used survival data as an endpoint; that design allowed more
than one treatment to be included in the second stage. Yao, Begg and Livingston
(1996) [56] proposed a design to screen new treatments as a continuous process for
identifying promising new therapeutic agents, and determined the optimal sample
size to be used with their design. Yao and Venkatraman (1998) [57], and Wang and
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Leung (1998) [54] extended that design to two-stage and fully sequential designs.
Stout and Hardwick (2005) [45] developed a cost-based and constraint-based deci-
sion theoretic-approach to the design of screening trials. Rossell, Muller and Rosner
(2007) [39] proposed a screening design based on Bayesian decision theoretics that
uses optimal linear boundaries. Ding, Rosner and Muller (2008) [11] developed a
more systematic decision-making optimal phase II screening trial design using a util-
ity function that accounts for sampling costs and possible future payo. However,
none of these designs focus on screening combinations of multiple agents, a feature
which is central to the designs we proposed in this work.
We model the main and synergistic eects of the treatment agents using a
linear model, which facilitates borrowing information across the combinations. We
cast the screening problem into a Bayesian hypothesis testing problem by construct-
ing a series of hypotheses, each of which appoints one of the combinations as the
most ecacious treatment. We utilize an encompassing prior with non-local prior
constraints [25, 21] to accommodate the complex parameter constraints imposed by
the hypotheses. During the trial conduct, based on the observed data, we continu-
ously update the posterior probabilities of the hypotheses and use them to adaptively
allocate patients to eective combinations and select the best treatment. Extensive
simulation studies show that, compared to the standard (multi-arm) balanced facto-
rial design, the proposed design yields a signicantly higher probability of selecting
the best treatment. It also allocates more patients to ecacious treatments.
1.3 Interim Monitoring for Late-onset Responses
Phase II trial studies usually are single-arm trials which are conducted to
test the ecacy of experimental agents and decide whether agents are suciently
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promising to be sent to phase III trials. To avoid assigning unacceptable number of
patients to inferior treatments, interim monitoring is employed to stop the trial early
for futility if there is sucient evidence to determine the ineciency of experimental
agents. Many phase II trial designs with interim monitoring are proposed to evaluate
the ecacy of the experimental agents[29]. Simon (1988) [43] presented a optimal
two-stage design which minimizes the expected sample size. The early stopping
criteria is applied to make an early stopping decision for futility at the end of rst
stage. Thall, Simon and Estey (1996) [51] proposed a new exible statistical strategy
to continuously monitor both safety and ecacy in single-arm cancer clinical trials.
Wathen et al. (2008) [55] proposed a Bayesian single-arm phase II design to account
for heterogeneity between patient prognostic subgroups. The subgroup-specic early-
stopping rules are applied to allow terminate some subgroups and continue others.
Johnson and Cook (2009) [19] derived a new class of Bayesian designs based on
formal hypothesis tests using nonlocal alternative prior densities with continuous
monitoring.
In general, interim monitoring based on previous responses assumes that the
outcome could be observed shortly after the initiation of treatment such that the
outcomes of the patients enrolled in the trial have been completely observed by
the time of interim monitoring. However, this assumption may not always hold in
practice, for example the case of late-onset responses [4, 8, 9] which may occur long
after the assignment of treatment. Combining with the fast accrual rate, this would
result in large number of missing responses at the time of interim monitoring. To
address such late-onset responses, one possible approach is to suspend the accrual
and wait until the previously enrolled patients are fully followed. Obviously this
approach utilizes all the information and provides a good estimate of response rate.
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However, it leads to an infeasibly long trial and needs to suspend the trial frequently
which is not practical and inconvenient for trial administration. If we do not suspend
the accrual and assign a newly arriving patient to treatment immediately, those
patients under treatment might not have completed the assessment. At the time of
interim monitoring, the early stopping decision will only be made based on the fully
observed data thus far. This approach is also problematic which often overestimates
the response rate and terminates the trial unappropriate.
We propose a Bayesian single-arm phase II design with continuous monitoring
for estimating the response rate of the experimental drug. To address the issue of
unobserved responses at the decision making time, we propose an approach which is
built on missing data methodology. Specically, we treat the unobserved responses
as missing data and apply standard methods to estimate the response rate. We
propose a piece-wise exponential model to estimate the hazard function of time
to response data and handle the missing responses using the multiple imputation
approach. For the proposed methods, we do not need to suspend patient accrual
to wait for the full observation of the outcomes of patients under treatment. We
evaluate the operating characteristics of the proposed method through extensive
simulation studies. We show that the proposed method reduces the total length
of the trial duration and yields a desirable operating characteristics for dierent
physician-specied lower bounds of response rate with dierent true response rates.
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CHAPTER 2
A Bayesian Phase I/II Design for Oncology Clinical Trials of
Combinational Biological Agents
In this chapter, we introduce a phase I/II design to identify the BODC for
oncology trials combining biological agents. Biological agents are playing an increas-
ingly important role in oncology drug development. There are some unique features
for the biological agents. The toxicity of biological agents is usually tolerable within
the therapeutic dose range and may plateau at higher dose levels. In addition, the
dose-ecacy curves for these agents often follow a non-monotonic pattern in which
ecacy may decrease at higher dose levels. For cytotoxic agents, toxicity and ef-
cacy are typically assumed to monotonically increase with dose level. Therefore,
traditional dose-nding designs with a focus on nding the MTD are not suitable for
trials of biological agents. Novel designs that consider both the toxicity and ecacy
of these agents are in great demand.
We propose a dose-nding design that can explicitly account for the unique
properties of biological agents. A change-point model is proposed to reect the prop-
erty that the dose-toxicity surface of the combinational agents may plateau at higher
dose levels and a general logistic model with quadratic terms is applied to accom-
modate the possible non-monotonic pattern for the dose-ecacy relationship. Our
design is conducted in two stages: in stage I, we escalate doses along the diagonal
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of the dose combination matrix as a fast exploration of the dosing space; in stage
II, based on the observed toxicity and ecacy data from stages I and II, we contin-
uously update the posterior estimates of toxicity and ecacy and assign patients to
the most appropriate dose combination. To encourage sucient exploration of the
two-dimensional dose space, we propose a novel dose-nding algorithm which facili-
tates the identication of the BODC. We conducted extensive simulation studies to
evaluate the operating characteristics of our proposed design.
In following sections, we introduce the probability models and the phase I/II
design for nding the BODC. We apply our design to the lymphoma clinical trial and
examine the design's operating characteristics through extensive simulation studies.
2.1 Methods
2.1.1 Modeling Toxicity and Ecacy
Consider a trial combining J doses of biological agent A, denoted by a1 <
a2 <    < aJ , with K doses of biological agent B, denoted by b1 < b2 <    <
bK . Without loss of generality, we assume J  K and that the dose values of
the aj's and bk's have been standardized to have mean 0 and standard deviation
of 0.5. This standardization is used to anticipate the prior elicitation in Section
2.1.2. Let (aj; bk) denote the combination of dose aj and dose bk, and let pjk and qjk
denote the toxicity and ecacy probabilities of (aj; bk), respectively, for j = 1; 2; :::; J;
and k = 1; 2; :::; K. Here, toxicity and ecacy are two binary events that reect
the side eects (toxicity) and therapeutic eects (ecacy) of the biological agents.
Therefore, pjk and qjk are simply the probabilities of the toxicity event and ecacy
event, respectively, at dose combination (aj, bk). Specically, the toxicity probability
indicates the probability that a subject experiences dose-limiting toxicity and the
ecacy probability represents the probability that there exists a direct or surrogate
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marker of ecacy. The ecacy event can be tumor shrinkage or pathological response
given by clinicians. The goal of the trial is to identify the BODC in the J K dose
combination matrix.
A change-point model for toxicity
Unlike cytotoxic agents, for which toxicity typically is assumed to monoton-
ically increase with the dose level, the toxicity of biological agents may initially
increase at low doses and then plateau at high doses. To accommodate this prop-
erty of biological agents, we describe pjk, the toxicity probability of (aj; bk), using a
change-point model
(2.1) logit(pjk) = (0+1aj+2bk)I(0+1aj+2bk  !)+!I(0+1aj+2bk > !);
where I() is the indicator function and (0; 1; 2, !) are unknown parameters.
Under this model, the shape of the dose-toxicity surface initially is monotonic with
the dose level but changes to at once it passes the threshold dened by 0+ 1aj +
2bk = ! (see Figure 2.1). We assume that 1 > 0 and 2 > 0 such that the toxicity
probability initially increases with the doses of A and B before it plateaus, at which
time the toxicity probability is given by e!=(1 + e!). We choose the change-point
model for the dose-toxicity surface because of its intuitive interpretation and the
ability to capture the threshold eect that may occur in some biological agents.
Nevertheless, the choice of the toxicity model could be exible as long as the model
is able to accommodate the non-monotonic dose-toxicity relationship. For example,
an alternative model pjk = !  logit 1(0 + 1aj + 2bk) can also provide a good t
and yield good operating characteristics (results not shown).
In model (2.1), we did not include an interactive eect for the two agents
(e.g., an interaction term 3ajbk) because the reliable estimation of such an interac-
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tion term requires a large sample size (e.g., a few hundreds), which is typically not
available in phase I trials. Note that for the purpose of dose nding, we do not seek
to model the entire dose-toxicity surface but aim to obtain an adequate local t to
facilitate dose escalation and de-escalation. A model may provide a poor global t
to the entire dose-toxicity surface; however, as long as the model provides a good
local t around the current dose, it will lead to correct decisions of dose escalation
and selection. O'Quigley and Paoletti (2003) [34] showed that simple parsimonious
models often yield better operating characteristics than complex models for dose
nding. In addition, In the context of drug combination trials, Wang and Ivanova
(2005) [53] and Braun and Wang (2010) [6] found that a model without interaction
performed as well as one with interaction for dose nding.
A second-order logit model for ecacy
For biological agents, the dose-ecacy curve often follows a non-monotonic
pattern. For example, in immunotherapy trials, the dose-ecacy relationship could
be bell-shaped. That is, the most eective dose may be a dose in the middle of
the therapeutic dose ranges, and when a dose level is lower or higher than the most
eective dose, ecacy decreases. To incorporate such a non-monotonic pattern for
the dose-ecacy relationship, we assume that the ecacy probability of (aj; bk), that
is, qjk, follows a logistic model of the form
(2.2) logit(qjk) = 0 + 1aj + 2bk + 3a
2
j + 4b
2
k;
where (0; : : : ; 4) are unknown parameters. The quadratic terms render the model
adequate exibility to capture the non-monotonic shape of the dose-ecacy surface.
In this dose-ecacy model, we exclude the interaction eect ajbk for the same reason
described above.
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2.1.2 Likelihood and Prior Specication
Suppose that at a certain stage of the trial, among njk patients treated at the
paired dose (aj; bk), xjk and yjk patients have experienced dose-limiting toxicity and
ecacy, respectively, where j = 1;    ; J and k = 1;    ; K. Let  = f0; 1; 2g and
 = f0; 1; 2; 3; 4g denote the regression coecients in models (2.1) and (2.2).
The likelihood function of the observed data D = fxjk; yjkg can be expressed as
L(Dj!;;) /
JY
j=1
KY
k=1
p
xjk
jk (1  pjk)njk xjk  qyjkjk (1  qjk)njk yjk :
Let f(!), f(), and f() denote the prior distributions for !, , and , respectively.
Assuming prior independence among !, , and , we write the joint posterior dis-
tribution as
f(!;;jD) / L(Dj!;;)f(!)f()f();
from which the full conditional distributions can be obtained. The Gibbs sampler [12,
7] is used to obtain posterior draws of unknown parameters for statistical inferences.
For the prior specication of the ecacy model, we assign  a weakly infor-
mative default prior f() proposed by [13] for logistic regression. To use this default
prior, we rst scale the actual values of the clinical doses to standardized values
fajg and fbkg, which have mean 0 and standard deviation 0.5, and then assign an
independent Cauchy distribution with center 0 and scale 2.5, Cauchy(0, 2.5), to the
regression coecients 1;    ; 4, and a Cauchy distribution with center 0 and scale
10, Cauchy(0,10), to the intercept 0. The advantages of using the weakly infor-
mative priors include (1) these priors are diuse and provide reasonable coverage
of the plausible values of the parameters, (for example, the prior Cauchy(0, 10) for
the intercept expects the ecacy probability for an average case to be between 10 9
and 1   10 9); and (2) these priors are also appropriately regularized such that a
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dramatic change in ecacy probability (e.g., from 0.01 to 0.5) is unlikely when dose
changes by one level, which substantially improves the estimation stability while still
being vague enough to ensure that the data are able to dominate the priors [13].
For the toxicity model, we use the default prior Cauchy(0, 10) for intercept 0. We
assign 1 and 2 a gamma prior distribution with shape 0.5 and rate 0.5 to ensure
the monotonicity before the dose-toxicity surface reaches the change line in model
(2.1). To specify a prior for !, we assume that the toxicity probability at the plateau
is between 0.2 and 0.8, which corresponds to a value of ! ranging from -1.39 to 1.39.
Thus, we assign ! a normal prior N(0; 4), which provides sucient coverage for all
plausible toxicity probabilities at the plateau, given by e!=(1 + e!).
2.2 Trial design
The proposed phase I/II design consists of two stages. Stage I is a run-in
period, in which the goal is to explore the dose-combination space quickly and collect
preliminary data so that the proposed probability models can be reliably estimated
in stage II for systematic dose nding. We start stage I of the design by treating the
rst cohort of patients at the lowest dose combination (a1; b1), and then escalate the
dose along the diagonal of the dose combination matrix until we encounter a dose
combination that violates the safety requirement
(2.3) Pr(pjk < jD) > ;
where  denotes the target toxicity upper limit and  is a prespecied safety cuto.
If the dose matrix is not square (i.e., J > K), we rst escalate the dose along
the diagonal from (a1; b1) to (a2; b2) and so on until we reach (aK ; bK); thereafter,
we escalate the dose by holding the dose level of B at K and increasing the dose
level of A from (aK ; bK) to (aK+1; bK) and so on until we reach the highest dose
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combination (aJ ; bK). In stage I, only a small fraction of patients are enrolled into
the trial and the observed data are sparse. Therefore, in this stage, we evaluate the
safety requirement based on a simple beta-binomial model rather than the proposed
change-point toxicity model. Specically, we assume that the number of toxicities
xjk follows a binomial distribution Bi(njk; pjk), and that the toxicity probability pjk
follows a beta distribution Beta(; ) with two shape parameters  and . To ensure
that the data dominate the posterior distribution, we set =0.1 and =0.2. Under the
beta-binomial model, Pr(pjk < jD) = B(j + xjk;  + njk   xjk), where B() is the
cumulative density function for a beta distribution. In stage I we also collect ecacy
data; however, these data will not be used to determine the dose escalation. The
rationale is that in this initial phase, as long as the doses are safe, we should explore
the two-dimensional dose space as quickly as possible to learn the dose-toxicity and
dose-ecacy surfaces.
Whenever a dose combination (aj; bk) violates the safety requirement, i.e.,
Pr(pjk < jD)  , or we reach the highest dose combination (aJ ; bK), stage I is
then complete and the trial moves on to stage II. For this stage of the trial we invoke
the toxicity and ecacy models described in Section 2 for systematic dose nding.
Stage II dose nding is highlighted by two features. First, the proposed algorithm
encourages the exploration of untried dose combinations to avoid the problem of
trapping in suboptimal doses, which is of particular concern for combinations of
biological agents. Because of complex drug-drug interactions and non-monotonic
dose-response patterns, the assumed (simple) dose-response model is not expected
to estimate the true dose-response surface well, especially at the beginning of the trial
when only a few observations are available. Consequently, the resulting estimates
of ecacy and toxicity may substantially deviate from the truth, and the \optimal"
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dose identied based on these estimates may actually be a suboptimal dose. In other
words, the dose with the highest estimate of ecacy is not necessarily the one actually
having the highest ecacy. By intentionally visiting untried dose combinations, the
proposed method increases the chance of nding better combinations and avoids
trapping in suboptimal doses. Second, we introduce a concept of g-degree neighbor
and g-degree admissible neighbor to facilitate the dose nding on the two-dimensional
space, the details of which we describe next.
Assume that the current dose combination is (aj; bk) and dene g-degree neigh-
bors of (aj; bk), denoted by Ng, as dose combinations f(aj0 ; bk0)g whose dose levels
are dierent from (aj; bk) no more than g levels, i.e., Ng = f(aj0 ; bk0) : jj0   jj 
g and jk0   kj  gg. Note that the dose set of Ng includes the current dose com-
bination itself. We further dene a g-degree admissible dose set Ag = f(aj0 ; bk0) :
(aj0 ; bk0) 2 Ng; P r(pj0k0 < T jD) > g, which is a subset of the g-degree neighbors
Ng satisfying the pre-specied safety requirement Pr(pj0k0 < T jD) > . That is, Ag
contains the safe g-degree neighbors of the dose combination (aj; bk).
Let N denote the prespecied maximum sample size, N1 denote the number
of patients in stage I, and N2 = N   N1 be the total number of patients available
for stage II. Then the proposed dose-nding algorithm for stage II is described as
follows:
1. Based on the accumulated trial data, we determine the dose set Ag , where
g = minfg : Ag 6= ;; g  1g. That is, Ag is the nonempty admissible set
with the smallest degree g. If Ag does not exist, i.e., all investigational doses
violate the safety requirement, we terminate the trial.
2. In Ag , we identify the combination (aj ; bk) that has the highest posterior
mean of ecacy rate q^jk .
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3. If combination (aj ; bk) has not been used to treat any patient thus far, or all
doses in Ag have been used to treat patients, we assign the next cohort of
patients to (aj ; bk). However, if (aj ; bk) has been used to treat patients and
there are some untried doses in Ag , before we decide to assign the next cohort
of patients to (aj ; bk), we compare q^jk against the following threshold:
(2.4) q^jk >

N2   n2
N2

;
where n2 is the total number of patients that have been treated in stage II and
 is a known tuning parameter controlling how stringent the threshold is. If the
condition (2.4) is not satised, (aj ; bk) will be excluded from the admissible
set Ag and we return to step 2.
4. We continue the above steps until exhaustion of the sample size, and select as
the BODC the dose combination with the highest value of q^jk and satisfying the
safety requirement Pr(pjk < jD) > .
Remark 1: The threshold (2.4) plays a key role in adaptively encouraging the
exploration of untried doses and avoiding the problem of trapping in suboptimal
doses during dose nding. At the beginning of stage II, when patients have not
yet been treated in that stage, i.e., n2 = 0, the value of f(N2   n2)=N2g equals 1.
Consequently, condition (2.4) disallows treating patients at a dose that has been used
previously and supports the exploration of untried doses. This is a sensible action
because at the beginning of stage II the ecacy estimate q^jk is of large variability,
and we should give high priority to using new doses rather than putting too much
faith in the point estimate q^jk. Toward the end of the trial (i.e., n2  N2), we have
more precise estimates of q^jk based on the accumulated data. As f(N2   n2)=N2g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approaches 0, we essentially assign incoming patients to the dose combination with
the highest value of q^jk because condition (2.4) is almost always satised. In condition
(2.4), the tuning parameter  controls how fast f(N2   n2)=N2g decays from 1 to
0. The value of  can be calibrated to obtain desirable operating characteristics.
We summarize both stages of the proposed design as follows.
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The proposed algorithm for nding BODC. The trial starts with the treatment of the
rst cohort of patients at the lowest dose (a1; b1). Suppose that patients are being
treated at dose (aj; bk). A dose is safe if Pr(pjk < jD) > ; otherwise, the dose is
deemed toxic.
Stage I Run-in Period
I1 If dose (aj; bk) is safe, escalate the dose and treat the next cohort at (aj+1; bk+1).
If j = k = K, escalate the dose to (aj+1; bK). If (a1; b1) is deemed toxic,
terminate the trial.
I2 Stage I is complete when either dose (aj; bk) is deemed toxic or the highest
dose combination (aJ ; bK) is reached. Stage II then starts.
Stage II Systematic Dose Finding
II1 Based on the observed data, identify Ag as the nonempty set of safe neighbors
of (aj; bk) with minimum degree g
. If Ag does not exist (i.e., all experimental
doses are deemed toxic), terminate the trial.
II2 Among the doses in Ag , identify the dose (aj ; bk) with the highest posterior
mean of ecacy q^jk .
II3 (a) If njk = 0 or nrs 6= 0 for all (ar; bs) 2 Ag , treat the next cohort at dose
(aj ; bk).
(b) Otherwise,
8>>>>>>>><>>>>>>>>:
If q^jk >

N2 n2
N2

treat the next cohort at (aj ; bk);
If q^jk 

N2 n2
N2

remove dose (aj ; bk) from Ag
and go to step II2.
II4 Repeat steps II2-4 until exhaustion of the sample size. Select as the BODC
the dose combination with the highest q^jk among all safe doses.
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2.3 Numerical Studies
2.3.1 Operating Characteristics
We conducted extensive simulations to evaluate the operating characteristics
of the proposed phase I/II design. Step II3 in our design encourages exploration of
untried dose combinations when sample size is small. This is an important feature
of the proposed dose-nding algorithm. To evaluate the impact of this feature, we
compared the proposed design to a \greedy" design that is otherwise identical except
that it always assigns patients to the dose with the highest estimate of ecacy.
Technically, this means that the greedy design replaces the condition (2.4) with
q^jk > 0 so that the dose with the highest ecacy among admissible dose set Ag is
always selected.
We also compared our design with the phase I/II combination trial design
proposed by Mandrekar, Cui, and Sargent(2007) [31]. For convenience, we refer to
the latter design as the MCS design. The MCS design converts toxicity and ecacy
into a mutually exclusive trinary outcome (namely, \no ecacy and no toxicity,"
\ecacy without toxicity" and \toxicity") and then uses a continuation ratio model
to describe the relationship between this trinary outcome and the dose. To conduct
a trial, the MCS design continuously updates the posterior estimates of the model
parameters based on the observed data and assigns patients to the dose combination
with the highest estimate of the probability of ecacy without toxicity (i.e., the MCS
design adopts a greedy dose-nding algorithm).
We considered trials combining two biological agents, A and B, with a max-
imum sample size of 45 patients and a cohort size of 3. We investigated 8 dierent
dose-toxicity and dose-ecacy scenarios (see Table 2.1). The rst four scenarios
consider the 4  4 combination trials with 4 dose levels for both agents A and B,
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which were (0.075, 0.15, 0.225, 0.3) and (0.08, 0.16, 0.24, 0.32), respectively. We
set the toxicity upper limit  = 0:3. The last four scenarios were taken from the
work of Mandrekar, Cui, and Sargent (2007) [31], which involves the analysis of 53
combination trials with 5 doses of agent A, (0.60, 0.75, 0.90, 1.05, 1.35), and 3 doses
of agent B, (0.60, 0.90, 1.20). The toxicity upper limit was  = 0:33.
In the proposed design, we set the safety cuto  = 0:4 and the tuning pa-
rameter  = 2, and used 2,000 posterior samples of unknown parameters !, , and
 to make inference after 1,000 burn-in iterations based on the adaptive rejection
Metropolis sampling algorithm [14]. Under each scenario, we carried out 2,000 simu-
lated trials for each of the designs. We used C++ to implement the proposed design;
the simulation code is available upon request.
The simulation results under scenarios 1-4 are summarized in Table 2.2, in-
cluding the selection percentage for each dose combination as the BODC and the
percentage of patients allocated to each dose combination (shown as subscripts). In
scenario 1, the dose-toxicity surface initially increases with the dose levels of agents
A and B and then plateaus in the right upper corner of the dose combination matrix
with a toxicity probability of 0.25; the dose-ecacy relationship is non-monotonic,
characterized by ecacy monotonically increasing with agent A but not with agent B.
The true BODC is (a4; b2). Among the three designs, the proposed design performs
the best with the highest selection probability (31.0%) and allocates the highest per-
centage of patients (15.9%) to the target dose combination. The greedy design is
often trapped in the doses on the diagonal since it does not encourage exploration of
untried dose combinations. As a result, it incorrectly selects the dose combination
(a4; b4) as the BODC with the highest percentage. Moreover, the greedy design only
allocates 10.0% patients to the true BODC, which is more than 1/3 lower than the
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Table 2.1: Eight dose-toxicity and dose-ecacy scenarios for the simulation studies.
The target BODCs are bolded.
Agent B
Scenario Agent Toxicity probability Ecacy probability
A 1 2 3 4 1 2 3 4
1 4 .25 .25 .25 .25 .42 .60 .38 .32
3 .15 .25 .25 .25 .19 .44 .20 .18
2 .10 .25 .25 .25 .12 .29 .15 .10
1 .05 .10 .15 .25 .05 .22 .10 .08
2 4 .25 .25 .25 .25 .10 .29 .29 .42
3 .15 .25 .25 .25 .25 .35 .43 .60
2 .10 .25 .25 .25 .12 .24 .32 .39
1 .05 .10 .15 .25 .05 .14 .28 .32
3 4 .25 .25 .25 .25 .05 .12 .18 .26
3 .15 .25 .25 .25 .10 .15 .25 .30
2 .10 .25 .25 .25 .14 .18 .30 .43
1 .05 .10 .15 .25 .23 .28 .42 .60
4 4 .17 .25 .45 .55 .60 .35 .32 .28
3 .12 .16 .25 .43 .42 .30 .28 .25
2 .08 .10 .19 .22 .35 .28 .22 .20
1 .05 .08 .12 .18 .25 .23 .19 .16
5 5 .07 .09 .11 .48 .53 .64
4 .05 .07 .09 .29 .36 .51
3 .04 .06 .08 .19 .28 .45
2 .03 .05 .07 .13 .22 .40
1 .02 .04 .06 .10 .19 .38
6 5 .51 .52 .53 .19 .28 .45
4 .41 .42 .43 .19 .28 .45
3 .31 .32 .34 .19 .28 .45
2 .16 .18 .19 .19 .28 .45
1 .11 .13 .15 .19 .28 .45
7 5 .41 .42 .43 .15 .24 .42
4 .21 .22 .24 .43 .49 .61
3 .06 .08 .10 .62 .66 .74
2 .04 .05 .07 .43 .49 .61
1 .03 .05 .07 .24 .32 .48
8 5 .80 .81 .81 .15 .19 .19
4 .51 .52 .53 .34 .41 .48
3 .36 .37 .38 .43 .49 .61
2 .21 .22 .24 .53 .58 .68
1 .06 .08 .10 .62 .66 .74
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proposed design. The MCS design does not perform well, selecting the true BODC
only 9.2% of the times. Scenarios 2 and 3 share the same dose-toxicity surface as
scenario 1, i.e., toxicity initially increases and then plateaus, but possesses dierent
shapes of the dose-ecacy surface. In scenario 2, combination (a3; b4) has the highest
ecacy and is the true BODC. Our proposed design identies (a3; b4) with the high-
est selection percentage 33.1% and assigns 18.5% patients to that dose combination.
The greedy and MCS designs identify the true BODC 17.9% and 14.5% of the times
and assign only 9.3% and 9.4% of the patients to the target, respectively. In scenario
3, a monotonic dose-ecacy relationship is assumed for agent B but not for agent
A and the highest dose combination (a1; b4) is the true BODC. The proposed design
again outperforms the other two designs. Scenario 4 is constructed to examine the
case in which only toxicity monotonically increases with dose, but not ecacy. The
proposed design yields a selection percentage of 46.3%, which is higher than those of
the greedy design (39.1%) and the MCS design (26.5%).
The simulation results for trials with 5 3 combinations are shown in Table
2.3, indexed as scenarios 5-8. In scenario 5, toxicity is negligible for all dose combi-
nations and ecacy monotonically increases with dose. The greedy design exhibits
the best performance. This is mainly due to the coincidence that the greedy design
would rst escalate from dose combination (a1; b1) to (a3; b3) along the diagonal,
then escalate up to the dose combination (a5; b3) during the run-in period in stage I.
Therefore, after the initial dose escalation the greedy design would quickly identify
(a5; b3) as the most desirable dose without exploring o-diagonal untried doses. Nev-
ertheless, the proposed design exhibits a better performance than the MCS design.
In scenario 6, toxicity monotonically increases with doses of both agents A and B,
whereas ecacy only increases with agent B and is not aected by agent A. The
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selection percentage of the proposed design is lower than that of the MSC design by
6.2%, but higher than that of the greedy design. In scenario 7, the selection per-
centage of the proposed design is higher than that of the MCS design (37.2% versus
30.2%), and in scenario 8, the selection percentage of the MCS design is 9.6% higher
than the proposed design. In addition to the eight scenarios shown in Tables 2.2 and
2.3, we also considered additional scenarios (see Table 2.4) with dierent shapes of
dose-toxicity and dose-ecacy relationships. The simulation results are summarized
in Table 2.5 and demonstrate that the proposed design performs consistently well.
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Figure 2.1: Surface of the toxicity probabilities for combinational agents using the
proposed change-point model. Toxicity initially increases with dose level
and plateaus after reaching the change line.
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Table 2.4: Additional dose-toxicity and dose-ecacy scenarios for the simulation stud-
ies. The target BODCs are bolded.
Agent B
Scenario Agent Toxicity probability Ecacy probability
A 1 2 3 4 1 2 3 4
9 4 .14 .25 .25 .25 .19 .24 .39 .29
3 .09 .15 .18 .25 .33 .45 .60 .42
2 .04 .08 .13 .18 .14 .29 .37 .28
1 .02 .04 .07 .12 .04 .17 .28 .17
10 4 .14 .25 .25 .25 .42 .60 .38 .32
3 .09 .15 .18 .25 .19 .44 .20 .18
2 .04 .08 .13 .18 .12 .29 .15 .10
1 .02 .04 .07 .12 .05 .22 .10 .08
11 4 .14 .25 .25 .25 .60 .35 .32 .28
3 .09 .15 .18 .25 .42 .30 .28 .25
2 .04 .08 .13 .18 .35 .28 .22 .20
1 .02 .04 .07 .12 .25 .23 .19 .16
12 4 .40 .40 .40 .40 .19 .24 .39 .29
3 .15 .18 .20 .25 .33 .45 .60 .42
2 .08 .12 .16 .20 .14 .29 .37 .28
1 .01 .05 .12 .17 .04 .17 .28 .17
13 4 .40 .40 .40 .40 .10 .10 .18 .24
3 .15 .18 .20 .25 .14 .14 .24 .43
2 .08 .12 .16 .20 .23 .28 .42 .60
1 .01 .05 .12 .17 .08 .10 .29 .42
14 4 .15 .18 .21 .25 .10 .10 .18 .24
3 .10 .15 .19 .23 .14 .14 .24 .43
2 .05 .12 .15 .20 .23 .28 .42 .60
1 .01 .07 .12 .18 .08 .10 .29 .42
15 4 .15 .18 .21 .25 .42 .60 .38 .32
3 .10 .15 .19 .23 .19 .44 .20 .18
2 .05 .12 .15 .20 .12 .29 .15 .10
1 .01 .07 .12 .18 .05 .22 .10 .08
29
Table 2.4 continued.
Agent B
Scenario Agent Toxicity probability Ecacy probability
A 1 2 3 4 1 2 3 4
16 4 .15 .18 .21 .25 .19 .24 .39 .29
3 .10 .15 .19 .23 .33 .45 .60 .42
2 .05 .12 .15 .20 .14 .29 .37 .28
1 .01 .07 .12 .18 .04 .17 .28 .17
17 4 .17 .22 .45 .50 .42 .60 .38 .32
3 .12 .16 .25 .43 .19 .44 .20 .18
2 .08 .10 .19 .22 .12 .29 .15 .10
1 .05 .08 .12 .18 .05 .22 .10 .08
18 4 .17 .22 .45 .50 .10 .18 .24 .14
3 .12 .16 .25 .43 .13 .24 .37 .26
2 .08 .10 .19 .22 .24 .38 .60 .37
1 .05 .08 .12 .18 .10 .23 .42 .22
19 4 .17 .22 .45 .50 .10 .10 .18 .24
3 .12 .16 .25 .43 .14 .14 .24 .43
2 .08 .10 .19 .22 .23 .28 .42 .60
1 .05 .08 .12 .18 .08 .10 .29 .42
20 4 .06 .07 .08 .10 .24 .20 .15 .10
3 .05 .06 .07 .08 .60 .43 .35 .25
2 .04 .04 .05 .06 .39 .32 .24 .12
1 .02 .03 .04 .05 .30 .20 .10 .05
21 4 .06 .07 .08 .10 .24 .18 .14 .10
3 .05 .06 .07 .08 .37 .26 .20 .13
2 .04 .04 .05 .06 .60 .37 .30 .24
1 .02 .03 .04 .05 .42 .22 .15 .10
22 4 .25 .25 .25 .25 .24 .20 .15 .10
3 .15 .25 .25 .25 .60 .43 .35 .25
2 .10 .25 .25 .25 .39 .32 .24 .12
1 .05 .10 .15 .25 .30 .20 .10 .05
23 4 .25 .25 .25 .25 .15 .10 .08 .05
3 .15 .25 .25 .25 .24 .18 .14 .10
2 .10 .25 .25 .25 .37 .26 .20 .13
1 .05 .10 .15 .25 .60 .37 .30 .24
30
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CHAPTER 3
Bayesian Adaptive Phase II Screening Design for
Combination Trials
In this chapter, we propose a Bayesian adaptive screening design for com-
bination trials. There is an increasing trend to use the combination therapies for
cancer treatment. Combination therapies can lead to treatment synergies that result
in improved patient outcomes. Therefore, the number of treatment combinations
that must be tested is often quite large. Conducting separate phase II trials on every
possible combination of treatments is often not practical. Novel designs that can test
the ecacy all combinations in a single trial are imperative.
Toward this goal, we describe a Bayesian adaptive trial design that facilitates
the pooling of information obtained across treatment combinations. We model the
main and synergistic eects of the treatment agents using a linear model, which
facilitates borrowing information across the combinations. We cast the screening
problem into a Bayesian hypothesis testing problem. We construct a series of hy-
potheses, each of which appoints one of the combinations as the most ecacious
treatment. We utilize an encompassing prior with non-local constraints to accom-
modate the complex parameter constraints imposed by the hypotheses. During the
trial conduct, based on the observed data, we continuously update the posterior
probabilities of the hypotheses and use them to adaptively allocate patients to eec-
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tive combinations and select the best treatment. We conduct extensive simulation
studies to evaluate the performance of the proposed design. The comparison to the
standard (multi-arm) balanced factorial design show that our proposed design selects
the best treatment with a signicantly higher probability and allocates more patients
to ecacious treatments.
In following sections, we describe our model, prior specication and trial
design. We examine the operating characteristics of our design using simulation
studies.
3.1 Methods
3.1.1 Probability Model
We consider trials to evaluate the treatment eects of all possible combi-
nations of k treatment agents, A1; A2;    ; and Ak. We assume that each drug
combination is assigned to one treatment arm, although it is straightforward to ex-
tend our design to trials where some combinations are excluded. Given k agents,
there are
 
k
r

dierent r-agent combinations, r = 0; 1;    ; k, resulting in a total of
p =
Pk
r=0
 
k
r

= 2k combinations, including placebo group, to be evaluated. The goal
of the trial is to identify the most ecacious treatment combination.
The outcome variable in the trial that motivates our research represents the
mean change in the patient-reported symptom score. We assume that the outcome
for the ith patient, yi, is continuous and follows a linear model of the form
(3.1)
yi = 0+1Ii(A1)+2Ii(A2)+  +1;2Ii(A1; A2)+  +1;2; ;kIi(A1; A2;    ; Ak)+i
where 0 is the intercept of the linear model and Ii() is an indicator of whether
patient i receives the given agents. For example, if patient i receives a combination
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of A1 and A2, then Ii(A1) = Ii(A2) = Ii(A1; A2) = 1; whereas all the other indicator
functions are then 0. Model (3.1) is exible and accounts for the main and interaction
eects of combining agents. Specically, k represents the main treatment eect of
Ak, k;k0 represents the two-way interaction or synergistic eect between Ak and Ak0
when k 6= k0, and so on. We assume that the residual i follows a normal distribution
with mean 0 and variance 2. Binary and time-to-event outcomes can be modeled
using a similar linear structure within a generalized linear model framework.
To cast the problem into a hypothesis testing framework, we dene the null
hypothesis H0 to assert that no treatment is better than the placebo, and a series
of alternative hypotheses H1; : : : ; Hp 1, where Hj asserts that the jth treatment
combination is superior to all others. In our trial, for example, treatment j is superior
to treatment k if it leads to a greater reduction in symptom burden. Let 0() denote
the eect of the placebo and let j(), j = 1; : : : ; p  1, denote the net treatment
eect of the jth combination (or treatment arm). Under the linear model (3.1),
the treatment eect, j(), is a linear combination of the regression parameters,
's. For example, the treatment eect of the combination of A1 and A2 is given by
j() = 0+1+2+1;2; and the treatment eect of the three-agent combination of
A1; A2 and A3 is j() = 0+1+2+3+1;2+1;3+2;3+1;2;3. To be consistent
with the lung cancer trial described in Section 1.2, we assume that a smaller value of
j() (i.e., less symptom burden) represents a better response. Then the hypotheses
can be formally expressed as
Hj : j() = min(0();    ; p 1()); j = 0;    ; p  1:
We let j(; 
2) denote the prior distribution assigned to the unknown parameters 
and 2 under Hj. Further discussion of the prior specication is provided in Section
2.3; for the moment we note that the domain of each prior is restricted to values of
36
 that are consistent with the hypothesis under which they are dened [21]. Given
these prior densities, the marginal density of the observed data y under Hj is
(3.2) mj(y) =
Z Z
f(yj; 2)j(; 2)d2d;
and the Bayes factor [23, 15] of Hi to Hj is given by
(3.3) Bij =
mi(y)
mj(y)
:
If p(Hj) denotes the prior probability of Hj, then the posterior probability of Hj
given the data y is
(3.4) p(Hjjy) = p(Hj)mj(y)Pp 1
i=0 p(Hi)mi(y)
=
"
p 1X
i=0
p(Hi)
p(Hj)
Bij
# 1
:
If we assume that all hypotheses are equally likely a priori, then the posterior prob-
ability of Hj simplies to
(3.5) p(Hjjy) = mj(y)Pp 1
i=0 mi(y)
=
"
p 1X
i=0
Bij
# 1
:
The value of p(Hjjy) has a very intuitive probability interpretation|the probability
that the jth combination is the best treatment conditional on the observed data.
Meanwhile, the value of p(H0jy) is the probability that the placebo is the best
treatment. Therefore, it provides a natural evidence-based mechanism to adaptively
assign patients to ecacious combinations and select the most promising combina-
tion.
3.1.2 Trial Design
We propose the following adaptive randomization scheme for the conduct of
the trial. We assume that a total of N patients are available for testing, and that
the rst m  p patients are equally randomized into the p treatment arms using m
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replications of a complete factorial design, i.e., m patients are randomized to each of
p arms. The advantage of using a factorial design is that it allows us to rapidly obtain
preliminary estimates of the main treatment eects. Following the lead-in factorial
phase of the design, subsequent patients are assigned to a treatment according to
the posterior probability that each treatment is best. The resulting design can be
described as follows.
1. Assign mp patients to the p treatment arms using m replications of a factorial
design.
2. For i = m p + 1; : : : ; N , randomize the ith patient to the jth treatment arm
with probability p(Hjjy), j = 0; : : : ; p   1, where y = (y1;    ; yi 1)0 are the
observed outcomes data from the rst i  1 patients.
3. At the end of the trial, we select the combination j that has the highest pos-
terior model probability, i.e., j = argmaxjp(Hjjy); j = 1;    ; p  1.
During the trial, we impose the following futility stopping rule: the trial is terminated
for futility if
maxfp(0   j > jy)g < ; j = 1;    ; p  1
where  and  are the prespecied minimal eect size and threshold, respectively.
That is, at any time during the trial, conditional on the observed data, if the proba-
bility of achieving an eect size of  for the best treatment arm is below the threshold
, we terminate the trial. In practice, the value of  can be elicited from investiga-
tors, and the values of design parameters m and  can be chosen by examining the
operating characteristics of the trial in simulation studies.
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3.1.3 Delayed Outcomes
In general, outcome-dependent adaptive randomization, such as the one we
have proposed, assumes that the outcome is quickly ascertainable so that when an
incoming patient is ready for randomization, the previous patients have been as-
sessed and their outcomes are completely observed. This assumption may not hold
in practice. In many cases, the patient outcomes require a long follow-up time to
be assessed (or the accrual is fast), so their outcomes are not available when a new
patient is randomized. To address this delayed outcome issue, one approach is to
suspend accrual and wait until the outcomes of patients treated in the trial are fully
observed. However, this approach is often not practical because it causes lengthy
delays in a trial, wastes patient resources, and causes administrative problems. Al-
ternatively, we propose to base our adaptive randomization scheme only on those
patient outcomes that are available at the time that each new patient is random-
ized. Our simulation studies in Section 3.2.1 show that, with nite samples, this
observed-data approach is competitive to the approach of suspending accrual.
3.1.4 Prior Specication and Derivation of Bayes Factor
We adopt the encompassing prior approach proposed by Klugkist et al. [25]
and Klugkist and Hoijtink [24] to set the prior distributions on  and 2 under
each hypothesis. In this approach, we rst specify a prior distribution for the un-
constrained model, and then based on that prior dene prior densities under each
hypothesis. More specically, we begin by assigning a noninformative prior to 2 of
the form (2) / 1=2. Given 2 and a hyperparameter g, we assume that  has a
normal prior density of the form (j2)  N(0; g2Ip), where Ip denotes a p  p
identity matrix.
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To modify the unconstrained priors for application to hypothesis Hj, j =
0; : : : ; p   1, we restrict the domain of  under each hypothesis so that it is con-
sistent with the assumptions of the given hypothesis [21]. That is, under hypoth-
esis Hj, the domain of  is restricted to the value space satisfying the condition
j() = min(0();    ; p 1()). This leads to the encompassing prior for Hj de-
ned according to
(3.6) j(
2) / 1
2
; j(j2) = 1
cj
N(0; g2Ip)Imin(j());
where Imin(j()) denotes an indicator function of whether j() = min(0();    ; p 1()),
and
cj =
Z
N(j0; g2Ip)Imin(j())d:
The prior densities used to dene each hypothesis are thus non-local with respect to
one another, which enables us to more rapidly exclude hypotheses that are inconsis-
tent with the data [21].
Under model (3.1) and the encompassing prior (3.6), the marginal density of
data y under hypothesis Hj is given by
mj =
Z Z
f(yj; 2)j(j2)(2)d2d
=
Z Z
N(yjX; 2In) 1
cj
N(j0; g2Ip)Imin(j()) 1
2
d2d
where
cj =
Z
N(j0; g2Ip)Imin(j())d:
Letting 0 = =, it follows that the normalizing constant
cj =
Z
N(0j0; gIp)Imin(j(0))d0
Recall that j(); j = 0;    ; p   1, is a linear function of , thus Imin(j(0)) =
Imin(j(
0)). Since  > 0, the order of fj(0)g is the same as that of fj(0)g.
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Thus
Imin(j(
0)) = Imin(j(
0))
and
cj =
Z
N(0j0; gIp)Imin(j(0))d0:
We can see that cj is independent of 
2 , which greatly simplies the evaluation of
the marginal density of y. Then it follows that
mj =
Z Z
N(yjX; 2In) 1
cj
N(j0; g2Ip)Imin(j()) 1
2
d2d
=
1
cj
Z Z
N(yjX; 2In)N(j0; g2Ip) 1
2
Imin(j())d
2d
=
 ((n+ p)=2)
cjgp=2(n+p)=2
Z 
(y  X)T (y  X) + 1
g
T
 (n+p)=2
Imin(j())d
=
 (n=2)
pjV j
cjgp=2n=2(yTy   TV  1)n=2
Z
t(;)Imin(j())d
Therefore the Bayes factor of Hi to Hj, Bij, is given by
Bij =
mi(y)
mj(y)
=
ri=ci
rj=cj
:
where
rj =
Z
t(;)Imin(j())d:
Here t() denotes a multivariate student distribution with degree of freedom  = n,
scale matrix  = V (yTy   TV  1)=n and median  = V XTy, where V =
(1
g
Ip + X
TX) 1, X is the design matrix in model (3.1) and n is the number of
patients who have completed the assessment during the course of the trial.
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3.2 Numerical Studies
3.2.1 Operating Characteristics
We evaluated the operating characteristics of the proposed Bayesian adaptive
screening (BAS) trial design through extensive simulation studies. In the context of
the lung cancer trial, we considered a total of 16 combinational treatments, including
the placebo control, that result from 4 agents (Table 3.1). Two hundred patients were
available for enrollment (i.e., N=200), and we performed m = 2 replications of the
factorial design to obtain preliminary estimates of the treatment eects. The accrual
rate was 12 patients per month, and it took 10 days to obtain the symptoms outcome.
Because the accrual was fast, we faced the delayed-outcome problem, that is, when a
new patient is accrued and ready for randomization, some patients treated in the trial
may have not nished their 10-day assessment and their outcomes are not available
for calculating the randomization probabilities for the new patient. To deal with this
issue, we adopted the observed-data approach described previously and calculated
the randomization probabilities based on observed data when the outcomes of some
patients are not available. Because the observed-data approach supports continuous
accrual, it took approximately 17 months to complete the trial. For this trial, the
approach of suspending accrual apparently is not feasible because it would lead to
an infeasibly long trial lasting at least 4.8 years. Although the accrual-suspension
approach is not useful in practice, it provides a theoretical benchmark for compar-
ison because it represents the optimal case that the complete data are available to
determine treatment assignment. For convenience, we denote the BAS design based
on the accrual-suspension approach as BASsusp. We congured the simulation pa-
rameters, , to generate 12 dierent ecacy scenarios. The simulation results of the
selection percentage of each treatment under these 12 dierent ecacy scenarios are
42
displayed in Table 3.2. The total selection percentage of target treatments and the
total percentage of patients assigned to targets are summarized in Table 3.3. Under
each scenario, the most ecacious combination was dened as the combination with
the smallest value of symptom burden, (). We set the residual variance 2 = 130
based on previous symptom report data. The two parameters involved in the futility
stopping rule,  and , were set to 0.35 and 10, respectively. We also compared the
proposed BAS design to a design based on 12 replications of the complete factorial
design on the 16 treatments, randomly allocating the last 8 available patients to
treatments. For the factorial design (FD), the treatment with the lowest value of the
least square estimate of () was selected as the best treatment at the end of the
trial. We carried out 2,000 simulations for each scenario.
Table 3.1: The 16 combinations of four agents (A1, A2, A3 and A4) investigated in the
lung cancer trial.
Treatment T0 T1 T2 T3 T4 T5 T6 T7
A1 0 1 0 0 0 1 1 1
A2 0 0 1 0 0 1 0 0
A3 0 0 0 1 0 0 1 0
A4 0 0 0 0 1 0 0 1
Treatment T8 T9 T10 T11 T12 T13 T14 T15
A1 0 0 0 1 1 1 0 1
A2 1 1 0 1 1 0 1 1
A3 1 0 1 1 0 1 1 1
A4 0 1 1 0 1 1 1 1
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Scenarios 1 to 4 simulated the cases in which there was a single best treatment.
In scenario 1, the best (or most ecacious) treatment was T1 (i.e., single agent A1),
and the BAS design substantially outperformed FD. The selection probability of
the target treatment T1 under the BAS design was 86.1%, while under FD it was
64.9%. In addition, compared to FD, the BAS design allocated a signicantly higher
percentage of patients to the best treatment (6.3% versus 39.3%, respectively). The
performance of the BAS design was rather similar to that of the optimal BASsusp
design. The selection probability of the target treatment under the BAS design
was only 1.1% lower than that of BASsusp design, and the percentage of patients
allocated to the best treatment were almost same in two designs (39.3% versus 39.1%,
respectively), suggesting that randomization based on observed data provided an
ecient way to handle delayed outcomes. In scenario 2, the best treatment was
T5, the combination of agents A1 and A2. In this case, the selection probability of
the BAS design was 21.5% higher than that of FD, and the BAS design assigned
32.8% more patients to the best treatment. In scenarios 3 and 4, the three-drug
combination T11 (i.e., combination of A1, A2 and A3) and the four-drug combination
T15 were dened as the optimal treatments. Comparisons under these scenarios were
similar to those made under scenarios 1 and 2. The selection probabilities of the
BAS design were more than 18% higher than these of FD, and the percentages of
patients assigned to the best treatment under the BAS design were more than 33%
higher than those under FD. Again, we observed that the performance of the BAS
design was rather similar to that of the BASsusp design.
Scenarios 5 to 8 were designed to evaluate the performance of the design when
there were two best treatments that were equally eective. In scenario 5, T1 and T2
were the target treatments with the highest ecacy. The BAS design selected T1 with
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a probability of 46.7% and T2 with a probability of 47.5%; whereas FD selected these
two targets with probabilities of 41.0% and 43.1%, respectively. That is, the total
selection probability of T1 and T2 under the BAS design was 10.1% higher than that
under FD. The percentage of patients assigned to the best treatment using the BAS
design was 38.8% higher than that using FD. For scenarios 6 to 8, the BAS design
again outperformed FD, achieving substantially higher selection probabilities and
assigning higher percentages of patients to the optimal treatments. Scenarios 9 and
10 had three optimal treatments, and scenario 11 had four target treatments. Under
these scenarios, the performance of the proposed BAS design once again dominated
that of FD. Compared to FD, the total selection probabilities of the target treatments
under the BAS design were improved by 0.7-5.9%, and the percentages of patients
assigned to the best treatments were improved by 39.8-44.6%. Scenario 12 represents
the case in which the treatment eects of all combinations are the same as that of
the placebo. Under this scenario, the BAS design and FD terminated the trial due
to futility, with respective probabilities of 85.2% and 90.5%.
As demonstrated in the simulation study, the proposed BAS design achieved
two important clinical goals simultaneously. First, it selected the best treatment
arms with high probability. Second, it allocated more patients to the best treat-
ments. This result seems somewhat surprising because the common notion is that
these two goals are in conict with each other. That is, it is often assumed that
randomization schemes in which patients are allocated to eective treatments have
less power to detect the best treatment at the end of the trial. This may be the case
in comparisons of only two or three treatments, but in more complicated settings in
which large numbers of treatments and treatment combinations are tested, the BAS
oers signicant gains in both power and patient allocation.
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The success of our adaptive randomization scheme in accomplishing both
goals simultaneously in high-dimension settings can be understood by noting that
our design allocates more patients to the subset of treatments that are competitive.
By reallocating patients away from ineective treatments, we obtain higher power
to distinguish between the top treatments. For example in scenario 1, our design
allocated 39.3 and 10.3 patients to the best and second best treatments (T1 and T15);
in contrast, FD allocated 6.3 patients to both T1 and T15. As a consequence, BAS
had higher power to distinguish between T1 and T15.
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Table 3.2: Operating characteristics of the proposed Bayesian adaptive screening
(BAS) design, BAS design based on the accrual-suspension approach
(BASsusp) and factorial design (FD). The ecacious treatments are bolded.
Treatment Eect
0 1 2 3 Selection percentage
4 5 6 7 of each treatment
8 9 10 11
12 13 14 15 BAS BASsusp FD
Scenario 1
0 -25 -13 -12 0.0 86.1 0.0 0.0 0.0 87.2 0.0 0.0 0.0 64.9 0.0 0.0
-11 -20 -19 -18 0.0 2.5 1.4 0.5 0.0 2.4 1.0 0.2 0.0 8.9 4.4 2.6
-14 -15 -12 -10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0
-16 -17 -14 -21 0.2 0.2 0.1 6.2 0.1 0.2 0.0 6.0 0.2 1.6 0.3 16.1
Scenario 2
0 -20 -12 -13 0.0 2.8 0.0 0.0 0.0 2.8 0.0 0.1 0.0 10.0 0.0 0.0
-11 -25 -19 -18 0.0 86.6 1.4 0.5 0.0 85.4 1.5 0.5 0.0 65.1 4.2 3.1
-14 -15 -12 -10 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.5 0.0 0.0
-16 -17 -14 -21 0.2 0.3 0.0 5.5 0.2 0.2 0.0 6.6 0.4 1.6 0.2 14.2
Scenario 3
0 -10 -12 -13 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1
-11 -20 -19 -18 0.0 3.3 1.2 0.6 0.0 2.5 1.1 0.7 0.0 8.6 4.5 2.9
-14 -15 -12 -25 0.0 0.0 0.0 86.0 0.0 0.0 0.0 87.5 0.1 0.2 0.1 67.6
-14 -17 -14 -21 0.1 0.1 0.2 6.2 0.0 0.2 0.0 5.7 0.2 1.3 0.1 13.5
Scenario 4
0 -16 -12 -13 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.7 0.0 0.0
-11 -20 -19 -18 0.0 3.5 1.0 0.2 0.0 2.1 1.0 0.5 0.0 9.1 4.1 2.7
-14 -15 -12 -10 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.4 0.0 0.0
-16 -21 -14 -25 0.0 5.7 0.0 86.8 0.1 6.5 0.0 86.5 1.0 14.4 0.1 66.6
Scenario 5
0 -25 -25 -13 0.0 46.7 47.5 0.0 0.0 46.1 48.8 0.0 0.0 41.0 43.1 0.0
-11 -20 -19 -18 0.0 1.0 0.2 0.2 0.0 0.6 0.3 0.0 0.0 4.1 2.0 1.4
-14 -15 -12 -10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
-16 -17 -14 -21 0.0 0.1 0.0 2.5 0.0 0.1 0.0 2.3 0.4 0.5 0.1 6.8
Scenario 6
0 -25 -12 -13 0.0 46.2 0.0 0.0 0.0 47.0 0.0 0.0 0.0 43.9 0.0 0.0
-11 -25 -19 -18 0.0 49.1 0.2 0.1 0.0 48.8 0.2 0.2 0.0 43.0 1.8 1.1
-14 -15 -12 -10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
-16 -17 -14 -21 0.1 0.0 0.0 1.7 0.0 0.0 0.0 1.5 0.2 0.9 0.0 8.3
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Table 3.2 continued.
Treatment Eect
0 1 2 3 Selection percentage
4 5 6 7 of each treatment
8 9 10 11
12 13 14 15 BAS BASsusp FD
Scenario 7
0 -25 -12 -13 0.0 46.3 0.0 0.0 0.0 47.9 0.0 0.0 0.0 42.1 0.0 0.0
-11 -20 -19 -18 0.0 0.8 0.4 0.2 0.0 0.8 0.2 0.2 0.0 4.3 2.1 0.9
-14 -15 -12 -25 0.0 0.0 0.0 48.5 0.0 0.0 0.0 46.8 0.0 0.0 0.0 41.3
-16 -17 -14 -21 0.0 0.0 0.0 1.8 0.0 0.2 0.0 2.0 0.2 0.7 0.0 7.7
Scenario 8
0 -25 -12 -13 0.0 47.5 0.0 0.0 0.0 49.4 0.0 0.0 0.0 43.8 0.0 0.2
-11 -20 -19 -18 0.0 0.8 0.5 0.1 0.0 0.4 0.0 0.2 0.0 5.1 2.5 1.8
-14 -15 -12 -10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0
-16 -17 -14 -25 0.1 0.1 0.0 48.7 0.0 0.0 0.0 48.3 0.2 0.9 0.1 44.5
Scenario 9
0 -25 -25 -13 0.0 31.3 31.5 0.0 0.0 33.4 30.9 0.0 0.0 31.1 32.0 0.0
-11 -25 -19 -18 0.0 34.1 0.3 0.0 0.0 33.4 0.2 0.0 0.0 29.2 1.2 0.5
-14 -15 -12 -10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
-16 -17 -14 -21 0.1 0.0 0.0 1.0 0.0 0.0 0.0 0.9 0.2 0.4 0.0 4.7
Scenario 10
0 -25 -25 -25 0.0 30.9 33.7 32.2 0.0 30.6 34.1 31.3 0.0 30.4 30.9 29.6
-11 -20 -19 -18 0.0 0.4 0.5 0.2 0.0 0.6 0.5 0.2 0.0 2.5 1.2 0.4
-14 -15 -12 -10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
-16 -17 -14 -21 0.0 0.0 0.0 1.1 0.0 0.0 0.0 1.1 0.1 0.3 0.0 4.2
Scenario 11
0 -25 -12 -13 0.0 23.5 0.0 0.0 0.0 26.3 0.0 0.0 0.0 25.9 0.0 0.0
-11 -25 -19 -18 0.0 25.7 0.2 0.2 0.0 25.4 0.2 0.0 0.0 22.7 0.8 0.6
-14 -15 -12 -25 0.0 0.0 0.0 24.7 0.0 0.0 0.0 24.6 0.0 0.0 0.0 25.2
-16 -17 -14 -25 0.0 0.0 0.0 24.6 0.0 0.0 0.1 22.7 0.0 0.2 0.0 24.0
Scenario 12
0 0 0 0 0.0 0.9 1.1 0.6 0.0 0.8 1.1 0.9 0.0 0.8 0.5 0.4
0 0 0 0 1.0 0.8 1.5 1.4 1.0 0.8 0.8 1.0 0.4 1.0 0.4 0.8
0 0 0 0 1.0 0.8 0.8 1.1 1.0 1.0 1.2 0.8 0.8 0.5 1.0 0.6
0 0 0 0 0.8 1.1 0.8 1.1 1.1 1.1 1.2 1.1 0.7 0.4 0.4 0.8
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Table 3.3: Summary of the simulation results, including the total selection percent-
age of target treatments and percentage of patients treated at the target
treatments.
Scenario 1 2 3 4 5 6 7 8 9 10 11 12
Total selection percentage of target treatments
BAS 86.1 86.6 86.0 86.8 94.2 95.3 94.8 96.2 96.9 96.8 98.5 85.2*
BASsusp 87.2 85.4 87.5 86.5 94.9 95.8 94.7 97.7 97.7 96.0 99.0 85.1*
FD 64.9 65.1 67.6 66.6 84.1 86.9 83.4 88.3 92.3 90.9 97.8 90.5*
Total percentage of patients treated at target treatments
BAS 39.3 39.0 39.2 39.8 51.3 54.7 51.2 55.9 61.5 58.6 69.6
BASsusp 39.1 38.7 40.4 40.0 51.8 54.6 51.2 56.8 61.6 58.5 69.5
FD 6.3 6.2 6.2 6.3 12.5 12.5 12.5 12.5 18.8 18.8 25.0
* the percentage of trials terminated due to futility.
3.2.2 Sensitivity Analysis
The encompassing prior for  requires pre-specication of the value for hy-
perparameter g. We conducted a sensitivity analysis to check the robustness of the
design to the value of g. Specically, we considered a tighter (or more informative)
prior with g = 5 and a more diused (or noninformative) prior with g = 20. Table
3.4 shows the results under scenarios 2, 4, 6, 8 and 10. Under each of these scenarios,
the results with g = 5 or 20 were very similar to these reported in Table 3.2 (with
g = 10), suggesting that the operating characteristics of the proposed design were
not sensitive to the specication of g as long as it was reasonably diuse. For exam-
ple, in scenario 2, the selection probabilities of the target treatment, T1, were 87.3%
and 87.1% under g = 5 and 20, respectively, which were very similar to that under
g = 10 (86.6%). The percentages of patients assigned to T1 were also very similar
for g = 5; 10 and 20.
We conducted another sensitivity analysis to examine the performance of the
proposed design when the outcome needs a longer assessment period to be evaluated.
We assumed an assessment period of 60 days and an accrual rate of 6 patients per
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month. As shown in Table 3.5, the results were very similar to these reported in
Table 3.2, in which the assessment period was 10 days with an accrual rate of 12
patients per month. This suggests that the proposed design is robust to the length
of the assessment period and delayed outcomes.
Table 3.4: Sensitivity analysis with dierent values of g under scenarios 2, 4, 6, 8 and 10
for the proposed Bayesian adaptive screening (BAS) design. The ecacious
treatments are bolded.
g = 5 g = 20
Scenario Selection percentage Selection percentage
2 0.0 2.6 0.0 0.0 0.0 2.8 0.0 0.0
0.0 87.3 1.1 0.5 0.0 87.1 1.2 0.4
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.1 0.2 0.0 5.9 0.2 0.3 0.2 5.1
4 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0
0.0 2.5 0.7 0.2 0.0 2.9 0.8 0.6
0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0
0.2 5.0 0.0 88.2 0.2 5.9 0.0 86.2
6 0.0 48.4 0.0 0.0 0.0 45.1 0.0 0.0
0.0 46.5 0.4 0.2 0.0 50.5 0.3 0.2
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.1 0.0 1.8 0.0 0.0 0.0 1.7
8 0.0 49.5 0.0 0.0 0.0 48.6 0.0 0.0
0.0 0.8 0.4 0.2 0.0 0.6 0.3 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.2 0.0 47.0 0.0 0.0 0.0 48.6
10 0.0 32.2 32.1 32.1 0.0 32.9 32.1 31.3
0.0 0.4 0.4 0.2 0.0 0.5 0.4 0.1
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 1.2 0.0 0.0 0.0 1.1
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Table 3.5: Sensitivity analysis for the proposed Bayesian adaptive screening (BAS)
design with an assessment period of 60 days and an accrual rate of 6 patients
per month. The ecacious treatments are bolded.
Selection percentage Selection percentage Selection percentage Selection percentage
Scenario 1 Scenario 2 Scenario 3 Scenario 4
0.0 86.5 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0
0.0 3.2 1.1 0.5 0.0 85.3 1.4 0.6 0.0 2.7 1.3 0.2 0.0 2.8 1.1 0.9
0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 86.0 0.0 0.0 0.0 0.0
0.2 0.3 0.0 5.3 0.1 0.3 0.2 5.7 0.0 0.2 0.2 6.6 0.2 6.2 0.0 84.8
Scenario 5 Scenario 6 Scenario 7 Scenario 8
0.0 48.5 45.6 0.0 0.0 47.9 0.0 0.0 0.0 47.2 0.0 0.0 0.0 48.4 0.0 0.0
0.0 0.7 0.3 0.4 0.0 47.0 0.3 0.4 0.0 0.8 0.6 0.4 0.0 0.8 0.2 0.2
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 46.2 0.0 0.0 0.0 0.0
0.0 0.2 0.0 1.7 0.0 0.0 0.0 1.6 0.0 0.0 0.0 2.6 0.1 0.1 0.0 47.8
Scenario 9 Scenario 10 Scenario 11 Scenario 12
0.0 31.9 31.9 0.0 0.0 32.3 32.0 31.8 0.0 24.2 0.0 0.1 0.0 1.0 1.0 1.2
0.0 32.4 0.2 0.2 0.0 0.6 0.4 0.1 0.0 24.6 0.4 0.2 0.9 1.1 1.2 1.1
0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 25.0 1.2 1.0 1.1 1.1
0.0 0.2 0.0 1.3 0.0 0.0 0.0 1.4 0.0 0.1 0.0 24.5 0.9 1.0 1.1 1.1
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CHAPTER 4
A Bayesian Phase II Design with Continuous Monitoring for
Late-Onset Responses Using Multiple Imputation
In this chapter, we propose a Bayesian single-arm phase II design with contin-
uous monitoring for late-onset responses. The interim monitoring rule is employed
to terminate the trial early for futility if there is sucient evidence to determine the
ineciency of experimental agents. The benets of the interim monitoring include
avoiding assigning an unacceptable number of patients to inferior treatments and
saving resources. In general, interim monitoring based on previous responses as-
sumes that the outcome could be observed shortly after the initiation of treatment.
Therefore, at the decision-making time, the outcomes of previous enrolled patients
have been completely observed. However, this assumption may not hold. For late-
onset responses, patient outcomes may occur long after the assignment of treatment.
With fast accrual rate, the amount of missing responses at the decision-making time
is large.
To address the issue of late-onset responses, we propose an approach built
on missing data methodology to handle the missing responses and apply standard
methods to estimate the response rate. Specically, we use a piece-wise exponential
model to estimate the hazard function of time to response data and use the multiple
imputation method to deal with unobserved responses. For the proposed methods,
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we do not need to interrupt patient accrual to wait for the full observation of previ-
ously patients that dramatically shortens the trial duration. We conducted extensive
simulation studies to evaluate the operating characteristics of the proposed method.
The comparison with standard, observed and complete methods show that the pro-
posed method reduces the total length of the trial duration and yields a desirable
operating characteristics for dierent physician-specied lower bounds of response
rate with dierent true response rates.
In following sections, we introduce the probability models and trial design
with interim monitoring. We propose a multiple imputation method to handle the
missing responses. We examine the operating characteristics of our proposed design
through extensive simulation studies and sensitivity analyses.
4.1 Methods
4.1.1 Probability model
Considering a single-arm phase II trial, we assume that subjects enter the trial
sequentially and each subject will be assessed for a xed assessment period of T . We
consider a binary response as a primary outcome variable for subject i during the
follow-up time, denoted by yi, where yi = 1 if treatment-related response is observed
in (0, T ) and yi = 0 otherwise. The length of assessment time T is chosen based on
previous knowledge to ensure that a treatment-related response event usually occur
within (0, T ). For dierent diseases and treatment agents, the evaluation period T
varies from days to months.
During the stage of the trial, suppose that n patients have entered the trial,
and let yi denote the binary response outcome for ith subject. Denoting the observed
response data for n subjects by y = fyi; i = 1;    ; ng, the likelihood function is given
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by
(4.1) L(yj) =
nY
i=1
yif1  g1 yi ;
where  denotes the response rate of the experimental treatment. Letting f()
denotes a prior distribution for , the posterior distribution of  is given by
(4.2) f(jy) = L(yj)f()R
L(yj)f()d :
For the conjugate prior specication of response rate , we set f() as a beta distri-
bution with two shape parameters  and , then the posterior distribution of  is a
beta distribution with shape parameters  +
Pn
i=1 yi and  + n 
Pn
i=1 yi. Here, we
suggest to use a vague or non-informative prior for .
4.1.2 Interim Monitoring and Late-onset Responses
Interim monitoring is usually conducted to stop the trial early for futility if
there is sucient evidence to demonstrate the ineciency of experimental drug. The
monitoring rules can be applied to the trial continuously or after a group with a xed
number of subjects. The advantage of interim monitoring is that if the experimental
treatment is deemed inecacious, we can stop the trial earlier and assign fewer
patients to the ineective treatment.
The stopping rule in our trial design is based on a physician-specied lower
bound of response rate for the experimental treatment, denoting by . If the true
response rate of the experimental treatment is higher than the lower bound , we
consider the experimental treatment to be ecacious and should continue recruiting
new arriving patients into the trial; otherwise, the trial should be terminated when
sucient information has been collected to demonstrate its futility. In our trial
design, we conduct continuous monitoring before each new patient entering the trial
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after n0 patients are completely followed. During the course of the trial, suppose that
n (n > n0) patients have entered the trial. If the posterior probability of response
rate achieving the physician-specied lower bound, , is less than a cut-o value,  ,
e.g., Pr( < ) >  , we stop the trial due to futility; otherwise the trial continues
recruiting new patients until the exhaustion of the total sample size N and concludes
that the experimental agent is suciently promising for further study. The inference
of the posterior estimates of response rate  is made given observed patient data by
the formula (4.2).
As mentioned before, continuous monitoring based on previous patients out-
comes needs outcomes to be assessed quickly after the initiation of the treatment.
However, it may not be the case for late-onset responses which may occur long after
the assignment of treatment. Before we discuss our method to address this issue,
we introduce the missing mechanism of the late-onset responses. In general, for
late-onset responses, the assessment time T usually is longer than the interarrival
time between two consecutive cohorts. Here, the interarrival time is dened as the
interval time between the entering time of two consecutive cohorts. If we denote the
patient interarrival time by  , it indicates that when  < T , some patients under the
treatment might have not yet exhibited responses or completed evaluation period
when new patient is ready to enter the trial. Specically, we denote the time to
response by ti for the ith subject and let ui (0  ui  T ) denote its actual follow-up
time at the moment of interim monitoring. If the actual follow-up time is less than
the true response time, i.e., ui < ti, it indicates that the patient response could not
be observed at the moment of interim monitoring. Therefore, responses are missing
only when patients have not yet experienced response (ui < ti) and have not fully
followed up to T (ui < T ). If patients either have experienced responses (ti  ui)
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or have completed followed-up (ui = T ) without experiencing responses, patients
outcomes are observed. Yuan and Yin (2012) showed that under this missing data
mechanism, the generated data are non-ignorable missing which means the proba-
bility of missingness of responses depends on the underlying missing outcomes. For
patients who will not experience responses during the whole assessment period, they
are more likely to have missing outcomes at the interim monitoring time compared
to patients who experienced responses.
As we know if the patient accrual rate increases, there would be more missing
responses at the same decision-making time. For example, considering a trial with
an assessment period of 3 months, if the accrual rate is 2 patients per month, i.e., the
interarrival time  = 1=2 months, there would be at most 6 missing outcomes at the
decision-making time. If we increase the accrual rate to 4 patients per month, i.e.,
the interarrival time  = 1=4 months, there would be at most 12 missing outcomes
at the decision-making time. Therefore, during the trial of conduct, the amount of
missing data depends on the ratio of of the assessment period T and the interarrival
time  . We denote this ratio by A=I ratio = T= . The larger the value of the ratio
is, the greater the amount of missing data would be.
Comparing with missing completely at random or missing at random, non-
ignorable missing data bring a new challenge to the trial design. To address the issue,
one possible approach is to suspend the accrual and wait until the previously enrolled
patients are fully followed-up. Therefore, the outcomes of all treated patients can
be observed and there is no unobserved response before new patient entering the
trial. Obviously, this method fully utilizes all available information and provides
a precise estimate of response rate at the time of decision-making time. However,
frequently suspension leads to an infeasibly long trial and brings inconvenience for
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trial administration.
If we do not suspend the accrual and assign a newly arriving patient to ex-
perimental treatment immediately, those patients under treatment might not have
completed the assessment period. A simple choice is to make early stopping deci-
sions solely based on the outcomes from patients who have completed the assessment
period or experienced responses during the assessment period. It means only the
complete data thus far are used at the moment of interim monitoring and the data
from the patients who have not completed the assessment period and not yet given
responses are ignored. However, this method has a higher chance to include patients
who would experience responses during the assessment period. The reason is that for
patients who would not experience responses in (0; T ), their responses are more likely
missing at the interim monitoring time compared to patients who would experience
responses in (0; T ). Therefore, this method is problematic and overestimates the
response rate. Another approach which does not suspend the accrual is to make in-
ference based on data from all treated subjects. For patients who have not completed
the assessment period, if there are no responses at the time of interim monitoring,
the current outcomes of no responses will be considered as the nal outcomes at the
end of assessment period. Specically, if the ith subject has not completed the eval-
uation period T and also has not experienced response, his/her response at the end
of assessment period is considered as censored, i.e., yi = 0. Although this approach
includes all the patients under the treatment, it uses current observed information to
replace the nal outcomes for the partially observed patients. Due to the property of
late-onset responses, these patients who have not completed the assessment period
are more likely to give responses at the remaining assessment period. The longer we
follow the patient, the higher probability that the patient will experience response
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later. Therefore, this approach is also problematic since it often underestimates the
response rate and terminates the trial unappropriate.
4.1.3 Multiple Imputation Approach
To address the missing-response issue introduced in previous section, we pro-
pose a method to handle the unobserved patient outcomes based on missing data
theory [30]. Dierent from above simple methods, this method is built on missing
data methodology and systematically treats the unobserved outcomes as missing
data. Intuitively, we rst ll in the missing data by the multiple imputation method
and then apply the standard complete-data method to the imputed dataset. Mul-
tiple imputation provides a systematic way to impute the missing response data
and meanwhile account for the sampling uncertainty due to the missing values [40].
Following this route, we replace each missing value with M imputed values, respec-
tively, i.e., we impute the missing data M times to form M lled-in datasets. Then
the standard complete-data methods can be applied to each of the lled-in datasets.
By combining the M complete-data inferences, we take into account the imputation
uncertainty.
To achieve the goal above, we specify a exible piecewise exponential model
for the time to response data during assessment period. Specically, we consider a
partition of the follow-up period [0; T ] into a nite number of K disjoint intervals
[0; h1); [h1; h2);    ; [hK 1; hK = T ] and assume a constant hazard k in the kth in-
terval. We dene the observed time xi = min(ui; ti) and ik = 1 if the ith subject ex-
periences response in the kth interval; and ik = 0 otherwise. Let  = f1;    ; Kg;
when fxig are completely observed, the likelihood function for n subjects based on
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observed time to response data D = fxi; ik; i = 1;    ; n; k = 1;    ; Kg is given by
(4.3) L(Dj) =
nY
i=1
KY
k=1
(k)
ikexpf keikg;
where eik = hk   hk 1 if xi > hk; eik = xi   hk 1 if xi 2 [hk 1; hk); and otherwise
eik = 0. K is the number of intervals dened for the piecewise exponential model.
Large K results in a nonparametric model of hazard function and unstable estimates;
small K lead to inadequate model tting. In our simulation studies, we conducted
sensitivity analysis with dierent values of K to check its robustness.
Let f() denote the joint prior distribution for all i's. We write the joint
posterior distribution as
f(jD) = L(Dj)f()R
L(Dj) :
For the prior specication of the piece-wise exponential model, we adopt a correlated
prior approach introduced in Qiou, Ravishanker and Dey (1999) [37]. Specically,
a discrete-time martingale process [1][2] is assigned to correlate the i's in adjacent
intervals, which introduces some smoothness to the estimates. Given (1;    ; k 1),
we specify that
kj1;    ; k 1  Gamma(ck; ck
k 1
); k = 1;    ; K
where Gamma(; ) represents a gamma distribution with a shape parameter  and
a scale parameter , so that E(kj1;    ; k 1) = k 1: The choice of the value
of 0 is suggested as follows. We assume a constant hazard function for the whole
assessment period, i.e., K = K 1 =    = 0. Then the value of 0 can be obtained
by setting the response rate at the end of assessment period as the physician specied
lower bound . The value of ck indicates the amount of information for smoothness
of k. If ck = 0, k is independent of k 1 while if ck !1, k = k 1.
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The conditional posterior distribution of k given 1;    ; k 1 and observed
data D is
f(kj1;    ; k 1;D) = L(jD)f(kj1;    ; k 1)R
L(jD)f(kj1;    ; k 1) :
After we obtained the full conditional distributions for each , the Gibbs sampler will
be used to obtain posterior draws of unknown parameters for statistical inferences.
We denote the binary response outcomes for subjects in the trial by y =
(yobs;ymis), where yobs and ymis denote the observed and missing response data,
respectively. To carry out the multiple imputation, we draw the missing binary
responses from its posterior predictive distribution which is given by
f(yijD) =
Z
f(yij)f(jD)d
The inference for informative missing responses is based on current observed time
to response data D which is more informative than observed binary data yobs. The
inference using only yobs would lead to biased estimates. Specically, we can drawM
independent sampling of the unknown parameter  with respect to its posterior dis-
tribution f(jD) given observed data D. Therefore, based on the posterior estimates
of , we can calculate the response rate of the experimental treatment at any time
t for 0 < t < T . Generally, if the ith subject has not experienced response at the
decision-making time given the actual follow-up time ui, i.e., t > ui, the conditional
probability that the ith subject would experience response during the assessment
period (0; T ) based on the posterior estimate of  is
^i() = Pr(t < T jt > ui) = Pr(t < T )  Pr(t < ui)
Pr(t > ui)
=
F (T )  F (ui)
F (ui)
where ^i() denotes the conditional response rate and F () is the cumulative dis-
tribution function of the random variable. In our piece-wise exponential model, the
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estimation of F (s) for any 0 < s < T can be obtained by F (s) = 1 PKk=1 exp( kek)
where ek = hk   hk 1 if s > hk; ek = s  hk 1 if s 2 [hk 1; hk); and otherwise ek = 0.
After we obtain the conditional response rate at the end of assessment period
for subject i, ^i(), we can easily nd that the full conditional distribution of binary
response yi 2 ymis is given by
f(yij) = Bernoulli(^i());
where Bernoulli() represents the probability density function of a Bernoulli distribu-
tion. Based on M independent posterior samplings of the parameter , we can draw
M independent samplings of yi 2 ymis from the above posterior distribution f(yij).
Here, the missing value yi generated in this way is drawn from its posterior predic-
tive distribution f(yijD). We construct M imputed datasets by lling in ymis with
M independent samples y
(m)
mis;m = 1;    ;M . Based on the mth imputed dataset
y(m) = fyobs;y(m)misg, we obtain the posterior distribution of the response rate (m) by
applying the simple Beta-Binomial model (4.1) and get the estimate of Pr((m) < ).
Then we combine the estimates of the response rate across M imputed datasets by
average and get the estimate of stopping criteria
Pr( < ) =
1
M
MX
m=1
Pr((m) < ):
If Pr( < ) >  , we stop the trial due to futility; otherwise, the trial continues
until the maximum sample size N is reached.
4.2 Numerical Studies
4.2.1 Operating Characteristics
In this chapter, we propose a multiple imputation method to handle unob-
served responses at the decision-making time for a single-arm phase II trial design.
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We conducted extensive simulation studies to evaluate the operating characteristics
of the proposed method. A maximum number of N = 50 patients were treated se-
quentially. The assessment period was set as T = 6 months and the interarrival time
between every two consecutive cohorts was  = 1 month, i.e., the A/I ratio=6. The
number of intervals for piece-wise exponential model used in multiple imputation ap-
proach is assumed as K = 6. Specically, we partitioned the assessment period [0; T ]
into K equal intervals, i.e., [0; 1
K
T ); [ 1
K
T; 2
K
T );    ; [K 1
K
T; T ]. We assigned a beta
distribution with  = 0:1 and  = 0:2 for f(). Under each scenario, we simulated
1,000 trials.
We considered three dierent lower bounds of response rate with  = 0:3; 0:4; 0:5,
respectively. Under each case of dierent lower bounds, we considered several sce-
narios with various true response rates of experimental treatment, denoted as Ft(T ).
Specically, for  = 0:3, we considered 5 scenarios with true response rates at 0.1,
0.2, 0.3, 0.4, and 0.5 respectively. For  = 0:4, we considered 5 scenarios with true
response rates at 0.2, 0.3, 0.4, 0.5, and 0.6 respectively. Similarly, for  = 0:5, we
considered 5 scenarios with true response rate as 0.3, 0.4, 0.5, 0.6, and 0.8 respec-
tively.
Under each scenario, we generated time to response data from a Weibull dis-
tribution. To generate the late-onset responses with dierent degrees of responses
occurring in latter half of the assessment period, (T=2; T ), we specify the Weibull
distribution with dierent shape and scale parameters. Specically, we choose the
scale and shape parameters of the Weibull distribution based on the following two
requirements. First, the true response rate at the end of follow-up indicates the value
of cumulative distribution function at t = T , where t is generated from Weibull dis-
tribution. Second, the probability of occurring responses during (T=2; T ) is xed
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at a pre-specied percentage, which represents the degrees of late-onset responses.
Therefore, based on the true response rate of experimental treatment and degrees
of late-onset responses, we specify the shape and scale parameters of the Weibull
distribution to generate the time to response data under each scenario. In our simu-
lations, we assumed approximately 50%, 70% and 90% responses would occur in the
later half of the assessment period (T=2; T ).
We compared the proposed multiple imputation methods (MI) to the stan-
dard method, complete method, and observed method which will be introduced here.
For convenience, we refer to the latter three methods as SD, CP and OB, respec-
tively. Basically, the simple Beta-Binomial model (4.1) is applied to estimate the
posterior distribution of response rate for these three methods. For SD, we suspend
the accrual and wait until the previously enrolled patients were fully followed-up.
This method utilizes all the information and provides a benchmark for comparison.
For the designs of CP and OB method, both recruit patients as the same rate with
the proposed design using MI method. However, CP and OB methods only use
partial information and lead to biased inferences resulting in terminating the trial
inappropriately. Specically, CP discards the missing responses and its inference is
solely based on the outcomes of patients who have completed the assessment period
or experienced responses during the assessment period. OB considers outcomes from
all the treated patients, but it uses current outcomes to replace the nal outcomes
if they still have not been observed at the decision-making time. As mentioned in
Section 2.2, CP and OB are both problematic with overestimation and underesti-
mation of response rate respectively. For all four designs, continuous monitoring is
conducted after n0 patients have been fully followed-up in the trial. Therefore, we
need to suspend the accrual after the n0th patient enters the trial for designs of MI,
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CP and OB. In our simulation studies, we set n0 = 5.
The simulation results are shown in Table 4.1. We compared MI to SD, CP
and OB in the terms of the average percentage of trial stopping, total number of
patients assigned to the treatment and the total trial duration under each scenario.
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Table 4.1: The percentage of trial stopping, total number of patients assigned to the
treatment and the total trial duration under the standard, complete, ob-
served and multiple imputation methods.
percentage of stop # of patients trial duration
Ft(T ) SD CP OB MI SD CP OB MI SD CP OB MI
Response lower bound =0.3, 90% response in (T=2; T ); A=I = 6
0.1 99.3 98.8 99.7 98.8 9.5 11.8 8.2 11.1 55.7 16.8 13.2 16.2
0.2 75.3 70.6 89.0 74.5 23.9 27.0 16.6 25.4 136.9 33.5 22.1 31.7
0.3 33.5 29.8 57.6 33.7 37.2 39.1 28.1 37.8 207.7 47.6 35.2 46.1
0.4 10.3 9.7 29.4 10.7 45.8 46.1 38.4 45.8 248.7 55.7 46.9 55.3
0.5 3.0 3.0 11.7 3.3 48.7 48.7 45.2 48.6 256.3 58.5 54.6 58.4
Response lower bound =0.4, 90% response in (T=2; T ); A=I = 6
0.2 98.7 96.4 99.6 97.5 12.4 16.6 8.8 15.1 70.7 21.8 13.8 20.2
0.3 71.5 64.3 89.1 70.3 26.0 30.2 15.8 27.6 144.9 37.0 21.4 34.1
0.4 30.1 23.8 59.7 29.5 39.0 41.9 27.3 40.1 211.6 50.8 34.3 48.6
0.5 9.0 6.4 32.3 8.8 46.3 47.7 36.9 46.8 244.1 57.3 45.2 56.4
0.6 2.0 1.2 13.0 2.5 49.1 49.5 44.7 49.0 251.4 59.4 54.0 58.9
Response lower bound =0.5, 90% response in (T=2; T ); A=I = 6
0.3 95.3 92.5 99.1 95.0 15.1 20.3 9.2 16.6 84.0 25.6 14.3 21.9
0.4 63.7 56.3 88.8 67.9 28.7 34.0 15.8 27.8 155.2 41.1 21.4 34.5
0.5 25.2 20.0 63.5 32.7 41.2 44.0 25.1 38.8 217.1 53.0 32.0 47.2
0.6 6.4 4.5 37.3 11.5 47.4 48.4 35.1 45.5 242.3 58.1 43.3 55.0
0.8 0.3 0.2 4.3 0.7 49.9 49.9 48.2 49.7 237.4 59.9 58.0 59.7
Response lower bound =0.3, 70% response in (T=2; T ); A=I = 6
0.1 99.3 98.5 99.8 98.9 9.8 12.4 8.5 11.4 56.8 17.5 13.5 16.5
0.2 76.2 68.1 87.4 75.9 23.2 27.4 17.1 25.0 128.9 33.9 22.7 31.2
0.3 33.6 27.9 51.4 33.3 37.3 39.5 30.4 38.0 199.1 48.1 37.8 46.3
0.4 9.3 8.7 22.0 9.7 46.1 46.5 41.3 46.1 235.8 56.1 50.2 55.7
0.5 4.5 3.9 10.5 4.5 48.0 48.2 45.6 48.0 235.2 58.1 55.1 57.8
Response lower bound =0.4, 70% response in (T=2; T ); A=I = 6
0.2 97.7 95.9 99.4 97.4 13.1 18.1 9.5 15.5 72.8 23.3 14.5 20.7
0.3 71.2 60.8 87.6 70.6 25.9 31.8 16.8 28.1 138.5 38.8 22.4 34.6
0.4 28.0 20.3 54.4 28.2 39.4 43.1 28.9 40.4 201.2 52.1 36.1 49.0
0.5 8.5 4.9 26.5 7.1 46.5 48.2 39.3 47.4 228.1 57.9 48.0 57.0
0.6 2.3 1.0 11.2 1.8 49.1 49.6 45.4 49.3 229.6 59.5 54.9 59.2
Response lower bound =0.5, 70% response in (T=2; T ); A=I = 6
0.3 95.9 92.3 99.2 96.5 14.4 20.9 9.7 15.9 76.9 26.2 14.7 21.1
0.4 65.3 54.7 86.8 67.1 28.5 35.4 17.0 28.9 145.9 42.7 22.7 35.5
0.5 27.5 17.2 59.6 31.7 40.3 44.7 27.1 39.3 197.5 53.9 34.1 47.7
0.6 6.2 3.7 28.9 9.3 47.5 48.6 38.5 46.5 221.7 58.5 47.0 56.0
0.8 0.6 0.2 3.4 0.8 49.8 49.9 48.6 49.7 208.4 59.9 58.4 59.6
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Table 4.1 continued.
percentage of stop # of patients trial duration
Ft(T ) SD CP OB MI SD CP OB MI SD CP OB MI
Response lower bound =0.3, 50% response in (T=2; T ); A=I = 6;K = 6
0.1 99.7 98.7 99.9 99.4 9.7 12.4 8.7 11.2 55.3 17.5 13.7 16.2
0.2 74.6 65.2 82.8 73.6 23.6 28.3 19.8 25.4 127.0 35.0 25.7 31.7
0.3 32.5 25.3 46.1 30.6 37.6 40.4 32.8 38.8 191.4 49.1 40.5 47.3
0.4 11.1 8.8 19.4 10.5 45.3 46.1 42.1 45.6 217.6 55.7 51.1 55.0
0.5 3.4 2.8 5.7 3.1 48.5 48.7 47.6 48.6 218.9 58.6 57.3 58.5
Response lower bound =0.4, 50% response in (T=2; T ); A=I = 6;K = 6
0.2 97.2 93.8 98.8 96.3 12.9 18.6 10.2 15.7 69.8 24.0 15.3 20.9
0.3 68.6 55.7 81.4 66.5 26.5 33.8 19.8 29.5 135.0 41.0 25.7 36.2
0.4 28.2 19.5 47.7 26.5 39.4 43.2 31.4 40.8 189.0 52.2 39.1 49.5
0.5 8.1 4.6 21.6 7.9 46.7 48.1 41.3 46.9 211.4 57.9 50.2 56.5
0.6 3.3 1.9 9.6 2.3 48.6 49.2 45.9 49.0 205.4 59.1 55.5 58.9
Response lower bound =0.5, 50% response in (T=2; T ); A=I = 6;K = 6
0.3 95.9 90.4 98.2 95.4 14.7 22.8 10.7 16.8 75.3 28.2 15.8 22.0
0.4 67.3 51.0 82.4 66.9 28.0 36.6 19.8 28.7 134.8 44.0 25.7 35.3
0.5 24.0 13.7 51.1 26.1 41.3 45.7 30.9 40.8 186.0 55.0 38.3 49.5
0.6 6.5 2.5 21.2 6.9 47.3 49.0 41.5 47.2 199.8 58.9 50.4 56.9
0.8 0.0 0.0 1.2 0.1 50.0 50.0 49.5 50.0 181.9 60.0 59.5 60.0
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First, we considered high skewed late-onset response data, i.e., 90% of re-
sponses would occur in the later half of the assessment period (T=2; T ). For the
scenario of the lower bound of response rate  = 0:3, if the true response rate
Ft(T ) = 0:1, the experimental treatment has lower ecacy and we should terminate
the trial early to avoid assigning more patients to it. Under this scenario, SD termi-
nates 99:3% trials for futility and assigns average 9.5 patients to the treatment. MI,
CP and OB perform very similarly with SD. They terminate the trial for futility at
the percentages of 98:8%, 98:8% and 99:7% and assign 11.1, 11.8 and 8.2 patients to
the treatment, respectively. For SD, because of frequently accrual suspension, the
trial duration is much longer than the other three methods. Considering the scenario
with the same lower bound  = 0:3, if the true response rate Ft(T ) = 0:2, we also
should terminate the trial early and assign fewer patients to the treatment. Under
this scenario, SD terminates 75:3% trials and assign 23.9 patients to the treatment.
Our proposed MI method performs much more closer results with SD, which ter-
minates 74:5% trials and assign 25.4 patients to the treatment. For CP, patients
who would experience responses during the assessment period are more likely to be
included for inference and therefore it overestimates the response rate which results
in low percentage of early stopping. Hence, CP terminates the trials with the per-
centage of 70:6%, which is lower than that of SD, and assigns 27.0 patients to the
treatment, which is higher than that of SD. OB considers the nal responses of par-
tially followed-up patients as no response. However, these patients might experience
responses during the remaining assessment period. Therefore, it results in under-
estimation of the response rate and high percentage of early stopping. Comparing
with SD, OB terminates the trials with lower percentage (89:0% versus 75:3%) and
assigns fewer patients (16.6 versus 23.9) to the treatment. When the true response
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rate Ft(T ) = 0:3, SD terminates trials with the percentage of 33:5% and assigns 37.2
patients to the treatment. MI still performs better than CP and OB. Comparing
with SD, its percentage of early stopping (33:5% versus 33:7%) and the number of
patients assigned to the treatment (37.2 versus 37.8) are both very close to the re-
sults of SD. For the scenarios of considering true response rates Ft(T ) = 0:4 and
Ft(T ) = 0:5, MI still has the best performance among all three methods, and has
very comparable results with SD. However, the trial duration of SD is much longer
than MI and results in a fatal implementation problem in the real trial. For all these
ve scenarios, CP outperforms than OB on average, since due to the high skewed
late-onset responses, very few patients would experience responses at the early part
of the assessment period which reduces the degree of overestimation for CP method.
Similarly, we considered ve scenarios with the lower bound  = 0:4 and another ve
scenarios with the lower bound  = 0:5. The same conclusion of MI outperforming
CP and OB is made for all scenarios.
To further evaluate the performance of our proposed method, we consid-
ered dierent degrees of responses occurring in latter half of the assessment period,
(T=2; T ). Similarly, we considered scenarios combining 70% of responses occurring
in (T=2; T ) with dierent lower bounds. Taking the case of the lower bound  = 0:4
as an example, we listed 5 scenarios with dierent true response rates Ft(T ). On
average, MI has very comparable results with SD and outperforms CP and OB.
Specically, considering Ft(T ) = 0:2, MI terminates the trial for futility with the
percentage of 97:4%, which is very close to the stopping percentage of SD (97:7%).
When the true response rate is set at Ft(T ) = 0:6 higher than the lower bound
 = 0:4, SD terminates only 2:3% of trials for futility. Under this scenario, MI
outperforms CP and OB again with stopping percentage at 1:8%. Meanwhile, MI
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assigns similar number of patients to the experimental drug comparing with SD, but
its trial duration is much shorter than the duration of SD. For the case of 50% of
responses would occur in the later half of the assessment period (T=2; T ), MI still
has very comparable performance with SD under many scenarios with dierent lower
bounds and true response rates.
4.2.2 Sensitivity Analysis
To further evaluate the performance of MI, we generated the late-onset data
from log-logistic distribution and compared the simulation results with SD, CP and
OB. We considered two cases: in one case setting the lower bound  at 0.4 with 90%
responses occurring in (T=2; T ); in the other setting the lower bound  at 0.5 with
70% responses occurring in (T=2; T ). The simulation results under these settings
are displayed in Table 4.2. From the table, we made the same conclusion comparing
with previous simulations which generate the time to response data from the Weibull
distribution. Specically, MI performs the comparable results with SD for both two
cases and outperforms CP and OB. Taking the rst case as an example, if the true
response rate Ft(T ) = 0:3, MI terminates the trial with 68:2% and assigns 28.1
patients to the treatment, which are very close to the results from SD (71:5% and
26.0).
We conducted sensitivity analyses to check the impact of parameter K and
A/I ratio. The simulation results are displayed in Table 4.3. We considered the case
of setting lower bound  = 0:4 and 90% responses occurring in (T=2; T ). The rst
ve rows represent the analysis of checking the robustness of parameter K under
dierent values of Ft(T ). Here, the A/I ratio is still set at 6, which is the same as
the settings of previous simulation results. Specically, we considered the scenarios
with K = 10; 12 and compared the results with the results in Table 4.1, which set
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K = 6 with the same  and late-onset degree. From the results, we found similar
simulation results for dierent values of K. For example, considering Ft(T ) = 0:2,
MI terminates the trial for futility with the percentages of 97:5%; 96:8% and 96:2%
for K = 6; 10; 12, respectively. MI also assigns the similar numbers of patients to the
treatment with the similar trial duration for dierent values of K. The results show
that the number of intervals for piece-wise model has negligible eect on the results
when it is set within a reasonable range.
Table 4.2: Sensitivity analysis for the proposed multiple imputation method with data
generated from log-logistic distribution.
percentage of stop # of patients trial duration
Ft(T ) SD CP OB MI SD CP OB MI SD CP OB MI
Time to event data is generated from log-logistic distribution
Response lower bound =0.4, 90% response in (T=2; T ); A=I = 6;K = 6
0.2 97.5 95.8 99.8 96.8 12.6 16.9 9.1 15.4 71.8 22.1 14.1 20.6
0.3 69.7 61.9 88.9 68.2 26.6 31.0 15.9 28.1 147.9 37.9 21.4 34.7
0.4 28.4 22.7 60.3 29.2 39.9 42.6 27.2 40.2 215.8 51.4 34.2 48.7
0.5 9.9 7.2 31.1 9.8 46.0 47.3 37.7 46.4 240.7 57.0 46.1 55.9
0.6 1.7 1.0 15.0 1.9 49.3 49.6 43.8 49.3 249.7 59.6 53.1 59.2
Response lower bound =0.5, 70% response in (T=2; T ); A=I = 6;K = 6
0.3 95.6 91.9 99.1 95.8 15.3 21.9 10.1 16.7 81.8 27.3 15.2 21.9
0.4 63.3 53.8 84.5 65.3 29.1 35.2 18.0 29.2 148.5 42.5 23.8 36.0
0.5 25.8 17.1 57.9 29.4 40.7 44.7 27.7 39.8 199.1 53.8 34.8 48.4
0.6 4.9 2.2 27.8 7.0 48.0 49.2 39.1 47.2 223.0 59.1 47.7 56.9
0.8 0.2 0.1 2.7 0.2 49.9 50.0 48.9 49.9 207.0 60.0 58.8 59.9
The last ve rows in Table 4.3 represent the analysis of checking the impact
of A/I ratio. For comparison, the parameter K is set at 6, which is the same with
the simulations in Table 4.1. We considered  = 0:4 and 90% late-onset degrees. We
considered the A/I ratio at larger values of 8, 12 and compared the results in Table
4.1, which set A/I ratio at 6 with the same  and late-onset degree. The larger
value of A/I ratio indicates faster accrual rate and higher percentage of missing
responses at the decision-making time. Therefore, it leads to a dicult case when
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A/I ratio increases. From the simulation results, we found that with higher A/I
ratio, MI incorrectly terminates the trial with a higher percentage for most scenarios.
Considering a scenario with true response rate Ft(T ) = 0:6, the stopping percentages
for A/I ratio at 6, 8, 12 are 2.5, 3.6, 3.9, respectively.
Table 4.3: Sensitivity analysis for the proposed multiple imputation method with dif-
ferent values of K and dierent values of A/I ratio
Ft(T ) % of stop # of patients trial duration % of stop # of patients trial duration
K=10 K=12
0.2 96.8 15.3 20.5 96.2 15.6 20.8
0.3 69.1 28.0 34.6 69.0 27.9 34.5
0.4 29.9 40.0 48.5 31.7 39.2 47.6
0.5 9.1 46.5 56.1 8.7 46.7 56.3
0.6 1.9 49.2 59.1 2.6 49.0 58.8
A/I=8 A/I=12
0.2 97.7 15.6 17.1 97.1 16.8 14.0
0.3 69.2 28.3 28.1 70.0 28.8 21.5
0.4 30.3 40.0 38.9 32.4 40.0 29.2
0.5 11.4 45.7 44.2 9.9 46.6 33.7
0.6 3.6 48.6 46.7 3.9 48.5 35.0
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CHAPTER 5
Conclusions
To account for the unique properties of biological agents, we proposed a new
Bayesian phase I/II design for trials that evaluate combinational biological agents.
A change-point model is used to capture the feature that the dose-toxicity surface
of biological agents may plateau at high dose levels, and a second-order logistic
model is employed to accommodate non-monotonic patterns for the dose-ecacy
relationship. We proposed a novel dose-nding algorithm that adaptively encourages
the exploration of two-dimensional dose-toxicity and dose-ecacy surfaces during
dose nding. In the early stage of the trial, the algorithm gives higher priority to
trying new doses, and toward the end of the trial it assigns patients to the most
eective dose that is safe. Extensive simulations show that the proposed design
has good operating characteristics with a high probability of selecting the BODC.
The advantage of our proposed design over the greedy design further veries the
importance of the dose-exploration algorithm incorporated in our design.
The proposed design is appropriate for trials in which toxicity and ecacy
outcomes are observed quickly. If toxicity and particularly ecacy cannot be ascer-
tained in a timely manner, the proposed design may be less useful. To handle delayed
toxicity and ecacy outcomes, we can extend our approach by modeling toxicity and
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ecacy as time-to-event outcomes to accommodate censored observations [22]. In
addition, in the proposed design, we are interested in nding the dose with highest
ecacy and tolerable toxicity as the target BODC. Our design can be easily extended
to the case that the target BODC is dened by a certain toxicity-ecacy trade-o
function. In that case, the main exercise is to elicit a reasonable toxicity-ecacy
trade-o (or utility) function from clinicians [47]. Once the trade-o is dened, our
design can be directly applied by replacing ecacy with the trade-o as the criteria
of dose escalation and selection.
To more eciently handle the large number of combination therapies that
must be tested, we proposed a Bayesian adaptive phase II screening design for trials
combining multiple agents. Rather than testing each of the combinations indepen-
dently, our design encompasses all the combinations of interest in a large screening
trial. We model the main and synergistic eects of the treatment agents using a linear
model and cast the screening problem into a Bayesian hypothesis testing problem.
By using a factorial lead-in phase, we are able to quickly obtain preliminary estimates
that each treatment combination is optimal, which enables us to quickly move into
the adaptive phase of the algorithm. We utilize the encompassing prior with non-
local constraints to accommodate the complex parameter constraints imposed by the
hypotheses, and we continuously update the posterior probability that each treat-
ment is best. Based on this posterior probability, we adaptively allocate patients to
eective combinations and select the best treatment. The proposed design substan-
tially outperformed a complete factorial design. Our design allocates more patients
to better treatments while at the same time providing higher power to identify the
best treatment at the end of the trial.
To address the unobserved responses for late-onset responses at the decision
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making time, we proposed a Bayesian single-arm phase II design for estimating the
response rate of the experimental drug. We conduct continuous monitoring to termi-
nate the trial early for futility and avoid assigning unacceptable number of patients
to inecacious treatments. We handle the missing responses using the multiple im-
putation approach by modeling the hazard function of time to response data using
a piece-wise exponential model. Extensive simulations show that the proposed de-
sign yields a desirable operating characteristics for dierent physician-specied lower
bounds of response rate with dierent true response rates. The proposed design
dramatically reduces the total length of the trial duration.
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